Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity

ABSTRACT

Common human diseases like diabetes and hypertension have been demonstrated to possess an associated genetic component composed of numerous underlying genetic defects. Traditional positional cloning of genes which possess the mutations responsible for complex disease has been hindered by both the low statistical power each locus may afford, and by the technically-laborious nature of the positional cloning methodologies. Disclosed herein is a methodology for the rapid identification of the genes responsible for quantitative trait loci (QTL) comprised of comprehensive gene expression analysis in organs relevant to disease in combination with the positional mapping of known QTL, so as to quantitatively identify candidate genes. This aforementioned methodology was applied to a total of five tissues/organs derived from the spontaneously hypertensive rat (SHR), the stroke-prone variant of the SHR (SHR-SP) and control Wistar Kyoto rats (WKY). Collectively these animals vary genetically in their predisposition to stroke, insulin sensitivity, blood pressure and body weight. These traits segregate into more than a dozen identified. The present invention discloses the differential-expression of sixty genes by GeneCalling® within five different tissues/organs among these animals. Additionally, five of the sixty genes were demonstrated to be localized within chromosomal regions linked to these traits of interest and possess amino acid substitutions which may contribute to the phenotype.

FIELD OF THE INVENTION

[0001] The present invention discloses a set of genes which have been demonstrated to be anomalously regulated (i.e., dysregulated) in a model of combining a pathophysiological predisposition towards stroke, hypertension, diabetes and obesity. The present invention also relates to methods of treating and/or preventing stroke, hypertension, diabetes or obesity by the administration of the nucleic acids or protein products (and derivative and analogs thereof) of the GENE SET which are defective and/or are of low abundance in humans. The present invention further relates to methodologies of diagnosis, prognosis and screening for alleles of the GENE SET which may cause or predispose to the aforementioned diseases.

BACKGROUND OF THE INVENTION

[0002] Prevalent human diseases such as hypertension, non-insulin dependent diabetes (NIDDM), stroke, and obesity (dyslipidemia) have been shown to possess a significant genetic component composed of multiple, perhaps numerous, underlying genetic defects. Human Metabolic Syndrome X, a relatively common but poorly understood disorder, has been shown to possess a significant genetic component which is comprise of an association of the pathophysiologies of hypertension, insulin resistance, dyslipidemia and abdominal obesity. See e.g., Ferrannini, et al., 1987. New Engi. J Med. 317:350-357; Kaplan, 1989. Arteriosclerosis 9:335-344. Given the prevalence of this combination of diseases, many research groups have focussed their efforts upon determining the etiology (i.e., the primary causative genetic defects) of Metabolic Syndrome X in humans and closely-associated animal models.

[0003] The most successfully studied of these aforementioned diseases to date is hypertension, with strong evidence nucleotide sequence variants, with their associated amino acid residue substitutions, within a total of 11 human genes affect blood pressure. See e.g., Shimkets, et al., 1994. Cell 79(3):407-414; Simon, et al., 1997. Nat. Genet. 17(2):171-178; Geller, et al, 1998. Nat. Genet. 19(3):279-281. While in all probability these variants, in toto, account for only a fraction of the variation in blood pressure within the general population, they, nonetheless, serve to illustrate the potential that the etiology of many such diseases may involve the interaction of a large number of genetic components. As the majority of the genetic components of complex diseases such as human Metabolic Syndrome X have yet to be elucidated, a comprehensive analysis for the genetic defects responsible for the phenotype was undertaken in the present invention within a closely-associated animal model of this syndrome.

[0004] The most widely-utilized and generally-accepted model of human Metabolic Syndrome X is the spontaneously hypertensive rat (SHR), which is characterized by the pathophysiologies of salt-induced hypertension, insulin resistance and increased abdominal fat. See e.g. Yamori, 1984. Experimental and Genetic Models of Hypertension In: Handbook of Hypertension (Elsevier Science Publishers, New York, N.Y.). While many genetic loci have been linked to various aspects of the SHR phenotype relative to those of the Wistar Kyoto (WKY) control strain, only a single gene defect has been implicated as a causative factor in the phenotype. See e.g., Aitman, et al., 1997. Nat. Genet. 16(2):197-201; Clark, et al., 1996. Hypertension 28(5):898-906; Bottger, et al., 1996. J Clin. Invest. 98(3):856-862. In addition, a spontaneous variant of the SHR was found which, in addition to the features of human Metabolic Syndrome X, undergoes severe hemmhoragic or ischemic stroke. This strain was designated SHR stroke-prone (SHR-SP). See e.g., Okamoto, et al, 1974. Circ. Res. 33/34:1-143-153; Rabattu, et al., 1996. Nat. Genet. 16(4):364-367. Prior to the present invention, the gene(s) influencing the manifestation and latency period of stroke within SHR-SP animals have also not been identified.

[0005] In order to identify the primary genetic defects leading to the phenotype of the SHR and SHR-SP, the present invention has included a comprehensive gene expression analysis utilizing the GeneCalling® technology to identify the majority of differentially-expressed genes between the strains of animals that were used for genetic linkage analysis. GeneCalling® not only identifies both known and novel differentially-expressed genes, but also identifies sequence variations in complementary DNA (cDNA) between the various strains being compared. These variations detected by GeneCalling® can include, but are not limited to, insertions, deletions and single base-pair changes.

[0006] In order to identify, in the most efficacious manner possible, which of the differentially-expressed genes may contribute directly to the phenotype, the genes were placed on the physical map of the rat using a radiation hybrid panel. Given the statistical improbability of each “event” occurring by chance, genes which were found to be both differentially-expressed within the different animal strains and tissues/organs and to map within quantitative trait loci (QTL), were deemed to have a high probability of possessing mutations which would affect the phenotype.

[0007] Presented herein is the first comprehensive organ survey of differences in gene expression in a genetic disease model coupled with a comprehensive mapping and mutation detection strategy to identify the gene(s) responsible for causing or predisposing to these aforementioned disease traits.

[0008] It should be noted that the citation or discussion of a reference herein shall not be construed as an admission that such is prior art to the present invention.

SUMMARY OF THE INVENTION

[0009] The present invention discloses the use of genes within a GENE SET, or mutations of the genes within the GENE SET, as diagnostics and therapeutics for disease.

[0010] More specifically, the present invention discloses nucleic acid sequences comprising the genes of a GENE SET, the proteins encoded therefrom and derivatives, analogs and mutations thereof, for use in the diagnosis, prognosis and screening, as well as the treatment, both prophylactic and therapeutic, of diseases such as hypertension, diabetes (insulin resistance), obesity/dyslipidemia and stroke (ischemic disease).

[0011] Further disclosed herein are methodologies of diagnosis, prognosis, and screening by detecting genes from the GENE SET. Diagnostic, prognostic and screening kits are also provided.

[0012] Additionally, the present invention also discloses methods of screening for modulators of GENE SET activity which affect hypertension, diabetes, obesity and both the latency period and severity of stroke.

BRIEF DESCRIPTION OF THE FIGURES

[0013] In order that the present invention disclosed herein is better understood and appreciated, the following detailed description is set forth.

[0014]FIG. 1: Illustrates multiple GeneCalling® fragments derived from the same gene. Independent gene fragments from 3-β-hydroxysteroid dehydrogenase/Δ-5-Δ-4 isomerase were found to be differentially-expressed, and the region of the cDNA from which they were derived is indicated. The red vertical line indicates the peak of the expression difference. Fragment length in nucleotides is indicated on the x-axis, relative peak intensity is indicated on the y-axis. Each trace represents the composite of multiple reactions from a single animal.

[0015]FIG. 2: Illustrates the differential-expression of selected genes. Data indicating differential expression of selected genes between the different genotypes is presented. In panel E, the GeneCalling® reaction identified a two base-pair deletion in the untranslated region of prepronatriodilatin which accounts for the shift of the peak from 172 to 170. The red vertical line indicates the peak of the expression difference. Fragment length in nucleotides is indicated on the x-axis, relative peak intensity is indicated on the y-axis. Each trace represents the composite of multiple reactions from a single animal.

[0016]FIG. 3: Illustrates the mapping of differentially-expressed candidate genes. Examples of mapping data of differentially-expressed genes are shown and the LOD score is indicated below each gene name. The vertical bar to the right of the map indicates the 95% confidence interval in which the gene lies.

[0017]FIG. 4: Illustrates the variation of amino acid residues found between WKY, SHR and SHR-SP genes. Predicted amino acid residue variation, based on nucleotide changes found in cDNAs encoding the proteins shown, are indicated by underlining. The first and last amino acid are numbered relative to the start of translation, as indicated in the corresponding GenBank entry.

[0018] Also shown are the amino acid sequences of the mutant human proteins consisting of: SGLT2 [SEQ ID NO:1]; kynurenine arninotransferase [SEQ ID NO:2]; FAT/CD36 [SEQ ID NOS:3 AND 4]; aldolase A [SEQ ID NO:5]; prepronatriodilatin [SEQ ID NO:6]; α-cardiac myosin [SEQ ID NO:7] and α-tubulin [SEQ ID NO:8].

[0019] Table 1: Total gene expression differences by genotype and organ. For each set of organs from each animal genotype that was compared, the number of gene fragments analyzed, the number of differences found and the percentage differences are illustrated.

[0020] Table 2: Differential gene expression between the SHR and WKY rats. Differential gene expression across a total of five (5) tissues is illustrated, where a “+” indicates increased mRNA abundance in the SHR and a “−” indicates a decreased MRNA abundance in the SHR. The chromosome to which the gene maps is provided and a “*” denotes that the gene maps to a position within a known QTL. In addition, amino acid residue substitutions which were identified by the present invention are also provided, where applicable. Table 3: Differential gene expression between the SHR-SP and SHR rats. Differential gene expression across a total of five (5) tissues is presented, where a “+” indicates increased mRNA abundance in the SHR-SP and a “−” indicates a decreased mRNA abundance in the SHR-SP. The chromosome to which the gene maps is provided and a “*” denotes that the gene maps to a position within a known QTL. In addition, amino acid residue substitutions which were identified by the present invention are also provided, where applicable.

DETAILED DESCRIPTION OF THE INVENTION

[0021] The present invention discloses a GENE SET comprising a total of 6 genes which were found to be both differentially-expressed and mutated (i e., possessing amino acid residue substitutions) between disease and control states in genetic rat models of hypertension, obesity. diabetes and stroke. The GENE SET (hereinafter “GENE SET”) includes; (i) CD36 (also known as fatty acid transport protein (FAT)); (ii) sodium dependent glucose co-transporter (SGLT2): (iii) aldolase A; (iv) kynurenine aminotransferase; (v) α-cardiac myosin and (vi) α-tubulin; as well as the previously-described mutation in the atrial natriuretic peptide (ANP).

[0022] Accordingly, the present invention relates to mutants of the proteins which are encoded by aforementioned GENE SET (and derivatives, fragments and homologs thereof) and the nucleic acids which encode them (and derivatives, fragments and homologs thereof), which function so as to increase predisposition to stroke, hypertension, diabetes and obesity.

[0023] The present invention relates to methods of diagnosis, prognosis and screening for stroke, hypertension, diabetes and obesity. In one embodiment, subjects are screened for a mutant allele of the GENE SET. In another embodiment, subjects are screened to differentiate the expression of mRNAs derived from the GENE SET, relative to their expression within controls.

[0024] The present invention also relates to methods of screening members of the GENE SET for the ability to affect the onset of, or predisposition to, hypertension, diabetes (insulin resistance) or obesity (dyslipidemia) or stroke, and to methodologies of screening for modulators (i.e., agonists, antagonists and inhibitors) of these genes.

[0025] (1) Mutated GENE SET

[0026] Proteins produced from the GENE SET, and mutants of derivatives, fragments, homologs and analogs of GENE SET proteins and the nucleic acids encoding the mutants, protein derivatives and protein analogs are disclosed by the present invention. The GENE SET mutants can be proteins possessing substitutions, deletions or insertions of one or more amino acid residues within the amino acid sequence wild-type GENE SET protein. Preferably, the GENE SET mutants are capable of binding to an anti-GENE SET antibody.

[0027] In another embodiment of the present invention, the GENE SET mutant increases latency to hypertension or stroke in stroke-prone rats (e.g., rats possessing the stroke-predisposing locus located on chromosome 1) which are fed a high salt diet (for example, but not limited to, a diet of 17.5% protein, 3.7 mg/g body weight Na⁺, 6.3 mg/kg body weight K⁺, and 0.03 mg/g body weight methionine and 1% NaCl drinking water).

[0028] Derivatives or analogs of GENE SET include, but are not limited to, those molecules comprising regions which are substantially homologous to the wild-type GENE SET or mutant GENE SET, or fragments thereof. For example, in various embodiments, at least 60-70% homology, preferably 70-80% homology, more preferably 90-95% homology and most preferably ≧95% homology over an amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is performed by a computer homology program known within the art, or whose encoding nucleic acid is capable of hybridizing to a coding GENE SET sequence, under stringent, moderately stringent, or non-stringent conditions.

[0029] The GENE SET, as well as fragments, derivatives, homologs and analogs GENE SET. ot the present invention can be produced by various methods known within the art. The manipulations which result in their production can occur at the gene or protein level. For example, the cloned GENE SET gene sequence can be modified by any of numerous strategies known within the art. See e.g., Sambrook, et al., 1990. Molecular Cloning, A Laboratory Manual, 2d ed (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The sequence of interest may be cleaved at appropriate sites with a restriction endonuclease (RE), followed by further enzymatic modification (if necessary), isolated, and ligated in vitro. In the production of the gene encoding a mutant, derivative or analog of the GENE SET, care should be taken to ensure that the modified gene remains within the same translational reading frame as the GENE SET and is uninterrupted by translational stop signals within the exonic region where the desired GENE SET activity is encoded.

[0030] The GENE SET-encoding nucleic acid sequence may be mutated in vitro or in vivo, to make changes within the coding regions (e.g., amino acid substitutions, additions or deletions) as well as to create and/or destroy translation, initiation, and/or termination sequences, or to form new restriction endonuclease sites or destroy pre-existing ones, to facilitate further in vitro modification. Any technique for mutagenesis known within the art may be utilized including, but not limited to, chemical mutagenesis; in vitro site-directed mutagenesis (see e.g., Hutchinson, et al, 1978. J Biol Chem. 253:6551); use of TAB7® linkers (Pharmacia), and the like.

[0031] Manipulations of the GENE SET sequence may also be made at the protein level. Included within the scope of the invention are GENE SET protein fragments or other derivatives or analogs which are differentially-modified during or after translation (e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protectingiblocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc). Any of numerous chemical modifications may be performed by known techniques, including but not limited to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc. Particularly included within the scope of the present invention are those modifications which reduce the level or activity of the GENE SET.

[0032] In addition, mutant GENE SET proteins (or analogs and derivatives thereof) which mediate the desired activity in vivo or in vitro, may be synthesized by use of a peptide synthesizer. Furthermore, if desired, non-classical amino acids or chemical amino acid analogs may be introduced as a substitution or addition into the GENE SET sequence. Non-classical amino acids include, but are not limited to: the D-isomers of the common amino acids, α-amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ-Abu, ε-Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine, fluoro-amino acids, designer amino acids such as β-methyl amino acids, Cα-methyl amino acids, Nα-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid may either be D (dextrorotary) or L (levorotary) isomers.

[0033] In another embodiment of the present invention, the GENE SET derivative is a chimeric, or fusion, protein comprising an GENE SET protein or fragment thereof (preferably consisting of at least 10 amino acids of the GENE SET protein or a mutant GENE SET protein) joined at its amino- or carboxyl-terminus via a peptide bond to an amino acid sequence of a different protein. In one embodiment, such a chimeric protein is produced by recombinant expression of a nucleic acid encoding the protein (i.e., comprising a GENE SET-coding sequence joined in-frame to a coding sequence for a different protein). Such a chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques (e.g., by use of a peptide synthesizer). Chimeric genes comprising portions of the wild-type GENE SET or the mutant GENE SET fused to any heterologous protein-encoding sequences may be constructed. A specific embodiment of the present invention discloses a chimeric protein comprising a fragment of GENE SET or mutant GENE SET of at least six amino acids.

[0034] Additionally, due to the degeneracy of nucleotide-coding sequences, other DNA sequences which encode substantially the same amino acid sequence as the mutant GENE SET of the present invention may be utilized in the practice of the present invention. The genes indigenous to the mutant GENE SET may be obtained by alteration of nucleotide sequences comprising all or portions of GENE SET gene by the substitution of different codons which encode the desired amino acid. For example, one or more amino acid residues within the sequence may be substituted by another amino acid of a similar polarity which acts as a functional equivalent, resulting in a “silent alteration.” Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, the nonpolar (hydrophobic) amino acids include, but are not limited to, alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. The polar neutral amino acids include, but are not limited to, glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. The positively charged (basic) amino acids include, but are not limited to, arginine, lysine and histidine. The negatively charged (acidic) amino acids include, but are not limited to, aspartic acid and glutamic acid.

[0035] In addition, the present invention discloses mutant GENE SET molecules, containing the aforementioned mutations for mutant GENE SET molecules.

[0036] (2) Nucleic Acid Sequences and Proteins of the GENE SET

[0037] GENE SET proteins and nucleic acids can be obtained by any methodology known within the art. The GENE SET amino acid and nucleotide sequences for, inter alia, human, rat, hamster, dog, mouse, bovine, porcine, equine, dogfish, Drosophila melanogaster and Xenopus are available in the public databases (e.g., GenBank).

[0038] Any eukaryotic cell potentially can serve as the nucleic acid source for the isolation of GENE SET nucleic acids. The nucleic acid sequences of the GENE SET may be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, primate, and like sources. The DNA may be obtained by standard protocols known within the art from cloned DNA (e.g., a DNA “library”), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA (or fragments thereof) purified from the desired cell. See e.g., Sambrook, et al., 1990. Molecular Cloning, A Laboratory Manual, 2d ed (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.); Glover, 1985. DNA Cloning: A Practical Approach (MRL Press, Ltd., Oxford, U.K.). Clones which are derived from genomic DNA may contain regulatory and non-coding, intron DNA regions, in addition to coding, exonic regions; whereas clones which are derived from cDNA will contain only coding, exon sequences. Following isolation, the sequence of interest is then molecularly-cloned into a suitable vector for propagation.

[0039] In the molecular cloning of the gene from complementary DNA (cDNA), the cDNA is synthesized by reverse transcription from total cellular RNA or poly(A)⁺ mRNA by methods which are well-known within the art. The gene(s) of interest may also be obtained from genomic DNA, wherein random DNA fragments are generated (e.g., by use of restriction endonucleases or by mechanical shearing), some of which will encode the desired sequence(s). The linear DNA fragments may then be separated as a function of their size by standard techniques including, but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography.

[0040] Once the DNA fragments have been generated, identification of the specific DNA fragment containing all or a portion of the GENE SET gene may be accomplished in a number of ways. In a preferred embodiment of the present invention, a GENE SET gene is isolated by use of the polymerase chain reaction (PCR), which can be utilized to amplify the desired GENE SET sequence within a genomic or cDNA library, or directly from genomic DNA or cDNA which has not been incorporated into a library. Synthetic oligonucleotides may then be utilized as primers in PCR-mediated amplification of sequences from an RNA or DNA source, preferably from a cDNA library, of potential interest. In addition, several different degenerate primers may be synthesized for use in the PCR amplification reactions. The PCR amplification reaction may be performed, for example, by use of a Perkin-Elmer Cetus® Thermal Cycler and Taq polymerase (Gene AmpJ).

[0041] It is also possible to vary the stringency of hybridization conditions utilized during the priming of the PCR amplification reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the known GENE SET nucleotide sequence and the nucleic acid of an GENE SET homolog being isolated. For cross-species hybridization, low stringency conditions are preferred. For same-species hybridization, moderately stringent conditions are preferred. Following successful amplification of a fragment or segment of a GENE SET homolog, that segment may be molecularly-cloned, sequenced and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, will permit the subsequent determination and isolation of the gene's complete nucleotide sequence. Alternately, PCR amplification may also be used to detect and quantitate GENE SET mRNA levels.

[0042] Additionally, a portion of a GENE SET gene or its associated mRNA (or a fragment thereof) may be purified, or an oligonucleotide synthesized, and the generated DNA fragments may be analyzed by nucleic acid hybridization to the labeled probe. See e.g., Benton & Davis. 1977. Science 196:180; Grunstein & Hogness, 1975. Proc. Natl. Acad Sc. U.S.A. 72:3961. Those DNA fragments which possess substantial homology to the labeled oligonucleotide probe will hybridize. GENE SET nucleic acids may be also identified and isolated by expression cloning using, for example, anti-GENE SET antibodies for selection. Alternatives to obtaining the GENE SET DNA by cloning or amplification include, but are not limited to, chemically synthesizing the gene sequence itself from the known GENE SET sequence or synthesizing a cDNA from the mRNA encoding the GENE SET protein of interest. It should be noted that the use of other methodologies is possible and within the scope of the present invention.

[0043] Once a clone has been obtained, its identity may be ascertained by nucleic acid sequencing and computer database-mediated comparison to known GENE SET sequences. DNA sequence analysis may be performed by any techniques known within the art including, but not limited to: chemical-based sequencing (see Maxam & Gilbert, 1980. Meth. Enzymol. 65:499-560); enzymatic dideoxynucleotide chain termination sequencing (see Sanger, et al., 1977. Proc. Natl. Acad. Sci. U.S.A. 74:5463); T7 DNA polymerase sequencing (see Tabor & Richardson, U.S. Pat. No. 4,795,699); automated DNA sequenator (e.g., Applied Biosystems, Foster City, Calif.) or the sequencing methodology described in PCT Publication WO 97/15690.

[0044] Nucleic acids which are hybridizable to a GENE SET nucleic acid (e.g., possessing a nucleotide sequence homologous or complementary to SEQ. ID NO:3 or NO:6), or a derivative or analog thereof, may be isolated by nucleic acid hybridization under conditions of low, moderate or high stringency. By way of example and not limitation, procedures using such conditions of low stringency are as follows (see also e.g., Shilo & Weinberg, 1981. Proc. Natl. Acad. Sci. USA 78:6789-6792): filters containing immobilized DNA were pre-hybridized for 6 hours at 40° C. in a solution containing 35% formamide, 5×SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 μ/ml denatured salmon sperm DNA. Hybridizations were performed in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate and 5-20×10⁶ cpm ³²P-labeled probe was utilized. The filters were incubated in hybridization mixture for 18-20 hours at 40° C., and then washed for 1.5 hour at 55° C. in a solution containing 2×SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA and 0.1% SDS. The wash solution was then replaced with fresh solution and the filters were re-incubated for an additional 1.5 hour at 60 C The filters were blotted dry and autoradiographed. If necessary, filters were washed for a third time at 65-68° C. and re-exposed to X-ray film. Various other conditions of low stringency hybridization which are well-known within the art may be utilized for low stringency hybridization protocols (e.g., as employed for cross-species hybridizations).

[0045] By way of example, but not of limitation, procedures utilizing conditions of moderate stringency hybridization are as follows: filters containing immobilized DNA were pre-hybridized for 6 hours at 55° C. in a solution containing 6×SSC, 5×Denhardt's solution, 0.5% SDS and 100 μg/ml denatured salmon sperm DNA. Hybridizations were performed in the same solution and 5-20×10⁶ cpm ³²P-labeled probe was utilized. The filters were incubated in hybridization mixture for 18-20 hours at 55° C. and then washed twice for 30 minutes at 60° C. in a solution containing 1×SSC and 0.1% SDS. Filters were then blotted dry and autoradiographed. Other conditions of moderate stringency hybridizations which may be utilized are well-known within the art.

[0046] Again, by way of example and not of limitation, procedures utilizing conditions of high stringency hybridization were as follows: pre-hybridization of filters containing immobilized DNA was carried out for 8 hours to overnight at 65° C. in buffer composed of 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μg/ml denatured salmon sperm DNA. Filters were hybridized for 48 hours at 65° C. in pre-hybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20 ×10⁶ cpm of ³²P-labeled probe. Washing of filters was done at 37° C. for 1 hour in a solution containing 2×SSC, 0.01% PVP, 0.01% Ficoll and 0.01% BSA. This was followed by a wash in 0.1×SSC at 50° C. for 45 minuets prior to autoradiography. Other conditions of high stringency hybridization which may be used are well-known within the art.

[0047] Nucleic acids encoding derivatives and analogs of GENE SET proteins, GENE SET anti-sense nucleic acids and primers which can be utilized to detect mutant GENE SET alleles and GENE SET gene expression are disclosed by the present invention. As used herein, a “nucleic acid encoding a fragment or portion of an GENE SET protein” refers to a nucleic acid encoding only the recited fragment or portion of the GENE SET protein, and not the other contiguous portions of the GENE SET protein as a continuous sequence.

[0048] GENE SET proteins (and derivatives, analogs and fragments thereof) of GENE SET proteins may be obtained by any method known within the art including, but not limited to, recombinant expression methods, purification from natural sources, chemical synthesis and the like. For example, GENE SET proteins may be obtained by recombinant protein expression techniques, wherein the GENE SET gene or portion thereof is inserted into an appropriate cloning vector for expression within a particular host cell. A large number of vector-host systems known within the art may be used. Possible vectors include, but are not limited to, bacteriophage (e.g., lambda derivatives); plasmids (e.g., pBR322, pUC plasmid derivatives or the Bluescript vector (Stratagene)) or other vector which are well-known within the art. The insertion of the DNA fragment of interest into a cloning vector may, for example, be accomplished by ligating the fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (e.g., linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative methodology, the digested vector and GENE SET gene may be modified by homopolymeric tailing. The recombinant molecule may subsequently introduced into the host cell via transformation, transfection, infection, electroporation, and the like, to facilitate the generation of a plurality of copies of the GENE SET gene sequence of interest.

[0049] In an alternative methodology, the desired gene may be identified and isolated after insertion into a suitable cloning vector in a “shot-gun” approach. Enrichment for the desired gene by, for example, size fractionation, may be performed prior to its insertion into the cloning vector.

[0050] In specific embodiments of the present invention, transformation of host cells with recombinant DNA molecules which incorporate the isolated GENE SET gene, cDNA or synthesized DNA sequence, facilitates the generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

[0051] The nucleotide sequence encoding a GENE SET protein (or a functionally-active analog, fragment or other derivative thereof), may be inserted into an appropriate expression vector (i.e., a vector which contains the necessary elements for the transcription and translation of the inserted protein-coding sequence). Alternately, the necessary transcriptional and translational signals may also be supplied by the native GENE SET gene and/or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence including, but are not limited to, mammalian cell systems infected with virus (e.g., vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g., baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be employed in the practice of the present invention.

[0052] Any of the methodologies previously-described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional/translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombinants (i.e., genetic recombination). Expression of nucleic acid sequence encoding a GENE SET protein or peptide fragment, may be regulated by a second nucleic acid sequence so that the GENE SET protein or peptide is expressed within a host cell which has been transformed with the recombinant DNA molecule. For example, expression of a GENE SET protein may be controlled by any promoter/enhancer element known within the art including, but not limited to: (i) the SV40 early promoter region (see e.g., Bernoist & Chambon, 1981. Nature 290:304-310); (ii) the promoter contained in the 3′-terminus long terminal repeat (LTR) of Rous sarcoma virus (see e.g., Yamamoto, et al., 1980. Cell 22:787-797); (iii) the Herpesvirus thymidine kinase promoter (see e.g., Wagner, et al., 1981. Proc. Natl. Acad Sci. U.S.A. 78:1441-1445); (iv) the regulatory sequences of the metallothionein gene (see e.g., Brinster, et al., 1982. Nature 296:39-42); (v) prokaryotic expression vectors such as the β-lactamase promoter (see e.g., Villa-Kamaroff, et al, 1978. Proc. Natl. Acad Sci. USA. 75:3727-3731) or the tac promoter (see e.g., DeBoer, et al., 1983. Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Additionally, the following animal transcriptional control regions, exhibiting tissue specificity, have been utilized in transgenic animals including: (i) the elastase I gene control region which is active in pancreatic acinar cells (see e.g., Swift, et al, 1984. Cell 38:639-646); (ii) the insulin gene-control region which is active in pancreatic β-cells (see e.g., Hanahan, 1985. Nature 315:115-122); (iii) the immunoglobulin gene control region which is active in lymphoid cells (see e.g., Grosschedl, et al., 1984. Cell 38:647-658; (iv) the α-1-antitrypsin gene control region which is active in the liver (see e.g., Kelsey, et al., 1987. Genes and Devel. 1:161-171) and the β-globin gene control region which is active in myeloid cells (see e.g., Mogram, et al., 1985. Nature 315:338-340.

[0053] In a specific embodiment of the present invention, a vector may be used which comprises a promoter operably-linked to a GENE SET-encoding nucleic acid, one or more origins of replication and, optionally, one or more selectable markers (e.g., an antibiotic resistance gene). In another specific embodiment, an expression construct is produced by sub-cloning a GENE SET coding sequence into the EcoRI restriction site of each of the three pGEX vectors (i.e., Glutathione S-Transferase expression vectors; Smith & Johnson, 1988. Gene 7:3140), thus allowing the expression of the GENE SET protein-product in the correct reading frame.

[0054] Expression vectors containing GENE SET gene inserts may be identified by the use of three general approaches: (i) nucleic acid hybridization; (ii) presence or absence of “marker” gene functions and (iii) expression of inserted nucleotide sequences. In the first approach, the presence of a GENE SET gene which has been inserted into an expression vector is detected by nucleic acid hybridization using oligonucleotide probes comprising sequences which are complementary to the aforementioned inserted GENE SET gene. In the second approach, the recombinant vector/host system is identified and selected based upon the presence or absence of certain “marker” gene functions (e.g., thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, and the like) which is caused by the insertion of the GENE SET gene of interest into the vector. Specifically, if the GENE SET gene is inserted into the marker gene sequence of the vector, the recombinant species possessing the GENE SET insert may be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors are identified by assaying the GENE SET protein product expressed by the recombinant. Such assays may be based, for example, upon the physical or functional properties of the GENE SET protein in various in vitro assay systems (e.g., binding of an anti-GENE SET protein antibody).

[0055] Following the isolation and identification of the recombinant DNA molecule of interest, several methodologies well-known within the art may be employed for its propagation. Once a suitable host system and growth conditions have been established, the recombinant expression vectors may be propagated and prepared in quantity. As previously disclosed, expression vectors which may be utilized include, but are not limited to the following vectors or their derivatives: human or animal viruses (e.g., vaccinia virus or adenovirus); insect viruses (e.g., baculovirus); yeast vectors; bacteriophage vectors (e.g., lambda), and plasmid and cosmid DNA vectors; and the like.

[0056] Similarly, a host cell strain may be chosen which modulates the expression of the inserted sequences or, alternately, modifies and processes the gene product in the specific fashion desired. Expression from certain promoters may be elevated by the presence of inducers; hence expression of the recombinant GENE SET protein may be controlled. Moreover, different host cells possess characteristic and/or specific mechanisms for the translational and post-translational processing and modification (e.g., glycosylation, phosphorylation of proteins), thus appropriate cell lines or host systems may be chosen to ensure the desired modification and processing of the recombinant protein is accomplished. For example, expression of the recombinant protein in a bacterial system can be used to produce an non-glycosylated core protein product; whereas expression in yeast will produce a glycosylated protein product. Similarly, expression in mammalian cells may be utilized to ensure “wild-type” glycosylation of a heterologous protein.

[0057] In other specific embodiments of the present invention, the GENE SET protein (or fragment, analog, or derivative) may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence of a different protein). These chimeric products may be produced by the ligation of the appropriate nucleic acid sequences encoding the desired amino acid sequences to one another, in the proper reading flame, by methods known within the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques (e.g., by use of a peptide synthesizer). It should be noted that the cloning and subsequent expression of both cDNA and genomic DNA sequences are within the scope of the present invention.

[0058] The recombinant GENE SET proteins of the present invention may also be isolated and purified by standard methods including chromatography (e.g., ion exchange, affinity, and partition column chromatography); centrifugation; differential solubility or by any other standard technique for the purification of proteins. In an alternate embodiment, native GENE SET proteins may be purified from natural sources utilizing standard methods such as those described above (e.g., immunoaffinity purification). In another embodiment, the GENE SET proteins may be synthesized by standard chemical methods known within the art (see e.g., Hunkapiller, et al., 1984. Nature 310:105-111). The functional properties of the GENE SET proteins may be evaluated using any suitable assay.

[0059] (3) Methods of Treatment

[0060] The present invention discloses methodologies of treating and preventing ischemic and metabolic diseases and disorders by administration of a therapeutic compound (hereinafter designated “Therapeutics”). In one embodiment, such “Therapeutics” include GENE SET mutant proteins (and derivatives, fragments and analogs thereof), as well as nucleic acids which encode the mutant GENE SET proteins (and derivatives, fragments or analogs thereof).

[0061] In another embodiment, the protein product, which are not produced as a direct result of the diminution of the activity of an enzyme indigenous to the GENE SET, may also be utilized as a Therapeutic of the present invention. As an example, but not a limitation, the mutation (i.e., amino acid substitution) in the kynurenine aminotransferase enzyme putatively blocks the enzyme's ability to produce kynurenic acid, a small, aqueous-soluble molecule which may function as an anti-hypertensive.

[0062] In another embodiment, the Therapeutic is a mutant GENE SET protein possessing one or more substitutions of amino acid residues relative to the “wild-type” GENE SET protein The subject to which the Therapeutic is administered is preferably an animal including, but not limited to, animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal. In a preferred embodiment, the subject is a human.

[0063] Generally, the administration of products of a species origin or species reactivity (in the case of antibodies) which is the same species as that of the subject is preferred. Thus, in a preferred embodiment, a human mutant GENE SET protein or nucleic acid (or derivative, fragment or analog thereof) is therapeutically or prophylactically administered to a human patient.

[0064] Accordingly, in a specific embodiment of the invention, GENE SET antagonists and inhibitors including, but not limited to, anti-GENE SET antibodies and GENE SET anti-sense nucleic acids and GENE SET derivatives (e.g., which function as competitive inhibitors of GENE SET) are administered to treat or prevent stroke or ischemic disease, hypertension, diabetes or obesity.

[0065] (a) Gene Therapy

[0066] In a specific embodiment of the present invention, nucleic acids comprising a sequence encoding a GENE SET mutant protein (or derivative thereof) or a GENE SET anti-sense nucleic acid, are administered by way of gene therapy. Gene therapy refers to therapy performed by the administration of a nucleic acid to a subject. In this embodiment of the invention, the nucleic acid produces its encoded protein or is an anti-sense nucleic acid which mediates a therapeutic effect. Any of the methods for gene therapy which are well-known within the art may be utilized in the practice of the present invention. See e.g., Ausubel, et al, 1993. Current Protocols in Molecular Biology (John Wiley & Sons, New York, N.Y.); Kriegler, 1990. Gene Transfer and Expression: A Laboratory Manual (Stockton Press, New York, N.Y.).

[0067] In a preferred embodiment, the Therapeutic comprises an GENE SET nucleic acid that is part of an expression vector that expresses an GENE SET protein or fragment or chimeric protein, preferably a mutant GENE SET protein or fragment or chimeric protein, or an GENE SET anti-sense nucleic acid thereof in a suitable host. In a specific embodiment, the nucleic acid possesses a promoter which is operably-linked to the mutant GENE SET coding region or to a sequence encoding an GENE SET anti-sense nucleic acid, wherein the promoter is inducible or constitutive and, optionally, tissue-specific. In another specific embodiment, a nucleic acid is used in which the mutant GENE SET coding sequences and any other desired sequences are flanked by regions which promote homologous recombination at a desired site in the genome, thus providing for intra-chromosomal expression of the mutant GENE SET nucleic acid. See e.g., Koller & Smithies, 1989. Proc. Natl Acad. Sci. USA 86:8932-8935. Delivery of the nucleic acid into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in which case, cells are first transformed with the nucleic acid in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

[0068] In a specific embodiment, the nucleic acid is directly administered in vivo, where it is expressed to produce the encoded product. This may be accomplished by any of numerous methods known in the art including, but not limited to, constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular by: (i) infection using a defective or attenuated retroviral or other viral vector (see e.g., U.S. Pat. No. 4,980,286); (ii) direct injection of naked DNA; (iii) use of microparticle bombardment; (iv) coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules; (v) by administering it in linkage to a peptide which is known to enter the nucleus; (vi) administering it in linkage to a ligand subject to receptor-mediated endocytosis which can be used to target cell types specifically-expressing the receptors and the like. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for cell specific uptake and expression, by targeting a specific receptor (see e.g., PCT Publications WO 92/06180 and WO 93/20221. Alternatively, the nucleic acid may be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination. See e.g., Zijlstra, et al., 1989. Nature 342:435438.

[0069] In a specific embodiment, a viral vector that contains the mutant GENE SET nucleic acid or codes for GENE SET anti-sense nucleic acid is used. For example, a retroviral vector can be used. See e.g., Miller, et al., 1993. Meth. Enzymol. 217:581-599. These retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. The GENE SET nucleic acid to be used in gene therapy is cloned into the vector, which facilitates delivery of the gene into a patient. See e.g, Clowes, et al, 1994. J Clin. Invest. 93:644-651; Kiem, et al., 1994. Blood 83:1467-1473.

[0070] Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. See e.g., Rosenfeld, et al, 1991 Science 252:431.-434; Mastrangeli, et al, 1993. J Clin. Invest. 91:225-234. In addition, adeno-associated virus (AAV) has also been proposed for use in gene therapy. See e.g., Walsh, et al., 1993. Proc. Soc. Exp. Biol. Med. 204:289-300 (1993).

[0071] Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient. In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, and the like. Numerous techniques are well-known within the art for the introduction of foreign genes into cells (see e.g., Loeffler & Behr, 1993. Meth Enzymol. 217:599-618) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and expressible by its cell progeny.

[0072] The resulting recombinant cells can be delivered to a patient by various methods known in the art. In a preferred embodiment, epithelial cells are injected (e.g., subcutaneously). In another embodiment, recombinant skin cells may be applied as a skin graft onto the patient. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be determined by one skilled in the art.

[0073] Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells (e.g, as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, and the like). In a preferred embodiment of the present invention, the cell used for gene therapy is autologous to the patient.

[0074] In an embodiment in which recombinant cells are used in gene therapy, a mutant GENE SET nucleic acid or nucleic acid encoding a GENE SET anti-sense nucleic acid is introduced into the cells such that it is expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and maintained in vitro may potentially be used in accordance with this embodiment of the present invention. Such stem cells include but are not limited to hematopoietic stem cells (HSC), stem cells of epithelial tissues such as the skin and the lining of the gut, embryonic heart muscle cells, liver stem cells (see e.g., PCT Publication WO 94/08598) and neural stem cells (see e.g., Stemple & Anderson. 1992. Cell 71:973-985).

[0075] Epithelial stem cells (ESCs) or keratinocytes can be obtained from tissues such as the skin and the lining of the gut by known procedures. See e.g., Rheinwald, 1980. Meth Cell Bio 21A:229. In stratified epithelial tissue such as the skin, renewal occurs by mitosis of stem cells within the germinal layer, the layer closest to the basal lamina ESCs or keratinocytes obtained from the skin or lining of the gut of a patient or donor can be grown in tissue culture. See e.g. Pittelkow & Scott, 1986. Mayo Clinic Proc. 61:771. If the ESCs are provided by a donor, a method for suppression of host versus graft reactivity (e.g., irradiation, drug or antibody administration to promote moderate immunosuppression) may also be utilized.

[0076] With respect to hematopoietic stem cells (HSC), any technique that provides for the isolation, propagation, and maintenance in vitro of HSC can be used in this embodiment of the invention. Techniques by which this may be accomplished include: (i) the isolation and establishment of HSC cultures from bone marrow cells isolated from the future host, or a donor or (ii) the use of previously established long-term HSC cultures, which may be allogeneic or xenogeneic. Non-autologous HSC are used preferably in conjunction with a method of suppressing transplantation immune reactions of the future host/patient. In a particular embodiment of the present invention, human bone marrow cells can be obtained from the posterior iliac crest by needle aspiration. See e.g, Kodo, et al., 1984. J Clin. Invest. 73:1377-1384. In a preferred embodiment of the present invention, the HSCs can be made highly enriched or in substantially-pure form. This enrichment can be accomplished before, during or after long-term culturing, and can be done by any techniques known in the art. Long-term cultures of bone marrow cells can be established and maintained by using, for example, modified Dexter cell culture techniques (see Dexter, et al., 1977. J Cell Physiol 91:335) or Witlock-Witte culture techniques (see Witlock & Witte, 1982. Proc. Natl. Acad. Sci. USA 79:3608-3612).

[0077] In a specific embodiment, the nucleic acid to be introduced for purposes of gene therapy comprises an inducible promoter operably-linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription.

[0078] (b) Anti-GENE SET Antibodies

[0079] In one embodiment of the present invention, as previously discussed hereinabove, antibodies which bind GENE SET proteins or nucleic acids (or derivative, fragments or analogs thereof) are used to treat or prevent hypertension, diabetes, obesity or ischemic stroke. Anti-GENE SET antibodies may also be used in the diagnostic, prognostic and screening methods the present invention. Such antibodies include, but are not limited to, polyclonal, monoclonal. chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment. antibodies to a human GENE SET protein are produced. In another specific embodiment, antibodies which reduce or inhibit GENE SET activity in vitro and/or in vivo, are provided.

[0080] Various procedures known in the art may be used for the production of polyclonal antibodies to an GENE SET protein or derivative or analog. In a particular embodiment, rabbit polyclonal antibodies to an epitope of a GENE SET protein (e.g., the protein of amino acid sequences SEQ ID NOS:1 and 4 or encoded by the nucleotide sequences of SEQ ID NOS:3 and 6, or a subsequence thereof) may be obtained. For the production of antibody, various host animals can be immunized by injection with the native GENE SET protein, a synthetic version, or a derivative or fragment thereof including, but not limited to, rabbits, mice, rats, and the like. Various adjuvants may be used to increase the immunological response, depending on the host species (e.g., Freund's adjuvant).

[0081] For preparation of monoclonal antibodies directed toward an GENE SET protein sequence (or derivative or analog thereof) any technique which provides for the production of antibody molecules by continuous in vitro cell lines may be used including, but not limited to: the hybridoma technique (see Kohler & Milstein, 1975. Nature 256:495-497); the trioma technique; the human B-cell hybridoma technique (see Kozbor, 1983. et aL, Immunology Today 4:72) and the EBV-hybridoma technique to produce human monoclonal antibodies (see Cole, et al, Monoclonal Antibodies and Cancer Therapy (Alan R. Liss, Inc., New York, N.Y.). In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals utilizing recent technology (see e.g., PCT Publication US90/02545). Human antibodies are within the scope of the present invention and may be obtained by using human hybridomas (see e.g., Cote, et al, 1983. Proc. Natil. Acad. Sci. U.S.A. 80:2026-2030) or by transforming human B-cells with Epstein-Barr virus (EBV) in vitro (see e.g., Cole, et al, 1985. Monoclonal Antibodies and Cancer Therapy (Alan R. Liss, New York, N.Y.). Additionally within the scope of the present invention are the production of “chimeric antibodies” (see e.g., Morrison, et al., 1984. Proc. Natl. Acad Sci. U.S.A. 81:6851-6855) which may be produced by splicing the genes from a mouse antibody molecule specific for GENE SET together with genes from a human antibody molecule of appropriate biological activity.

[0082] In one embodiment of the present invention, single chain antibodies (see U.S. Pat. No. 4,946,778) may be adapted to produce GENE SET-specific single chain antibodies. An additional embodiment of the invention discloses the utilization of Fab expression libraries (see e.g., Huse, et al., 1989. Science 246:1275-1281) so as to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for GENE SET proteins (or derivatives or analogs thereof).

[0083] Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab′)₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab′ fragments which can be generated by reducing the disulfide bridges of the F(ab′)₂ fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and F_(v) fragments.

[0084] In the production of antibodies, screening for the desired antibody may be accomplished by techniques known in the art (e.g., enzyme-linked immunosorbent assay(ELISA)). In a specific embodiment, the selection of antibodies which recognize a specific portion of an GENE SET protein may be accomplished by an assay which utilize hybridomas specific for a product which binds to a GENE SET fragment containing such portion. For selection of an antibody which possesses the ability to reduce or inhibit GENE SET activity, one may screen the antibody in any of the assays for GENE SET activity described infra.

[0085] (c) Anti-Sense GENE SET Nucleic Acids

[0086] In a specific embodiment of the present invention, the function of GENE SET protein(s) is reduced or inhibited by GENE SET anti-sense nucleic acids, utilized to treat or prevent stroke, hypertension, diabetes or obesity. The present invention provides the therapeutic or prophylactic use of nucleic acids of at least six nucleotides which are anti-sense to a gene or cDNA encoding GENE SET or a portion thereof. An GENE SET “anti-sense” nucleic acid, as utilized herein, refers to a nucleic acid species which is capable of hybridizing to a portion of an GENE SET RNA (preferably mRNA) by virtue of sequence complementarily. The anti-sense nucleic acid may be complementary to a coding and/or noncoding region of an GENE SET mRNA. Such anti-sense nucleic acids have utility as Therapeutics that reduce or inhibit GENE SET function, and can be used in the treatment or prevention of disorders as described, supra.

[0087] The GENE SET anti-sense nucleic acids are of at least six nucleotides and are preferably oligonucleotides (ranging from 6-150 nucleotides or, more preferably, 6-50 nucleotides). In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 15 nucleotides, at least 100 nucleotides, or at least 125 nucleotides. The oligonucleotides may be DNA, RNA or chimeric mixtures (or derivatives or modified versions thereof) and may be single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, or agents facilitating transport across the cell membrane (see e.g., Letsinger, et al., 1989. Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556) or blood-brain barrier (see e.g., PCT Publication No. WO 89/10134); hybridization-triggered cleavage agents (see e.g., Krol, et al, 1988. BioTechniques 6:958-976) or intercalating agents (see e.g., Zon, 1988. Pharm. Res. 5:539-549).

[0088] The GENE SET anti-sense nucleic acid of the present invention is preferably an oligonucleotide and more preferably, a single-stranded DNA. In a preferred embodiment, the oligonucleotide comprises a sequence anti-sense to a portion of human GENE SET. The oligonucleotide may be modified at any position on its structure with substituents generally known within the art.

[0089] Oligonucleotides of the invention may be synthesized by standard methods known within the art, for example, by use of an automated DNA synthesizer (e.g., Biosearch, Applied Biosystems, etc). As an example, but of limitation, phosphorothioate oligonucleotides may be synthesized by the method of Stein, et al., (1988. Nucl. Acids Res. 16:3209); methylphosphonate oligonucleotides may be prepared by use of controlled pore glass polymer supports (see e.g., Sarin, et al., 1988. Proc. Nati. Acad Sci. U.S.A. 85:7448-7451) and similar synthesis methodologies.

[0090] In a specific embodiment of the present invention, the GENE SET anti-sense oligonucleotide comprises catalytic RNA or a ribozyme (see e.g., PCT International Publication WO 90/11364; Sarver, et al., 1990. Science 247:1222-1225). In another specific embodiment, the oligonucleotide is a 2N-0-methylribonucleotide (see e.g., Inoue, et al., 1987. Nuc. Acids Res. 15:6131-6148) or a chimeric RNΔ-DNA analogue (see e.g., Inoue, et al., 1987. FEBS Lett. 215:327-330).

[0091] In another embodiment, the GENE SET anti-sense nucleic acid of the present invention is produced intracellularly by in vivo transcription from an exogenous sequence. For example, a vector may be introduced in vivo such that the vector (or a portion thereof) is transcribed, producing an anti-sense nucleic acid (RNA) of the present invention. Such a vector would contain a sequence encoding the GENE SET anti-sense nucleic acid, and can remain episomal or become chromosomally-integrated, so long as it can be transcribed to produce the desired anti-sense RNA. The aforementioned vectors may be comprised of plasmid, viral, or others known in the art which are utilized for replication and expression in mammalian cells and may be constructed by recombinant DNA technology methodologies standard within the art. Expression of the sequence encoding the GENE SET anti-sense RNA may be by any promoter known in the art to act in mammalian, preferably human, cells. Such promoters can be inducible or constitutive and include, but are not limited to: (i) the SV40 early promoter region (see e.g., Bernoist & Chambon, 1981. Nature 290:304-310); (ii) the promoter contained in the 3′-terminus long terminal repeat (LTR) of Rous sarcoma virus (see e.g., Yamamoto, et al., 1980. Cell 22:787-797); (iii) the Herpesvirus thymidine kinase promoter (see e.g., Wagner, et al., 1981. Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445); (iv) the regulatory sequences of the metallothionein gene (see e.g., Brinster, et al., 1982. Nature 296:39-42), and the like.

[0092] The anti-sense nucleic acids of the present invention comprise a sequence complementary to at least a portion of an RNA transcript of an GENE SET gene, preferably a human GENE-SET gene. However, absolute complementarily, although preferred, is not a requirement. A sequence “complementary to at least a portion of an RNA,” as utilized herein refers to a sequence possessing sufficient complementarily to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded GENE SET anti-sense nucleic acids. Similarly, a single strand of the duplex DNA or triplex formation may be assayed in a similar manner. The ability to hybridize will dependent upon both the degree of complementarily and the length of the anti-sense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with a an GENE SET RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art may ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[0093] The invention further provides pharmaceutical compositions (i.e., “Therapeutics”) comprising an effective amount of the GENE SET anti-sense nucleic acids of the present invention within a pharmaceutically acceptable carrier. In a specific embodiment, pharmaceutical compositions comprising GENE SET anti-sense nucleic acids may be administered via liposomes, microparticles, or microcapsules. It may be useful to use such compositions to achieve sustained release of the GENE SET anti-sense nucleic acids.

[0094] The amount of GENE SET anti-sense nucleic acid which will be effective in the treatment or prevention of ischemic disease will depend on the nature of the disease, and can be determined by standard clinical techniques. Where possible, it is desirable to determine the anti-sense cytotoxicity in cells in vitro, and then in useful animal model systems prior to testing and use in humans.

[0095] (4) Methods of Diagnosis, Prognosis and Screening

[0096] The present invention also discloses methodologies which relate to the diagnosis, prognosis and screening of stroke, hypertension, diabetes and/or obesity.

[0097] In one embodiment, anti-GENE SET-antibodies are used to detect and quantitate mutant GENE SET levels in one or more tissues (e.g., blood) of a subject by use of an immunoassay- based methodology. Specifically, such an immunoassay is performed by contacting a sample derived from a patient with an anti-GENE SET antibody under conditions such that immunospecific-binding can occur, and detecting or measuring the amount of any immunospecific-binding by the antibody. It should be noted, however, that the particular amino acid deletion, insertion or substitution within the amino acid sequence of the mutant GENE SET protein can change the epitope recognized by a specific anti-(wild-type) GENE SET antibody, such that antibody may bind the mutant GENE SET protein to a lesser extent, or not at all. Additionally, antibodies may be generated against the mutant GENE SET protein, or portion thereof, which bind specifically to the particular mutant GENE SET, but not the wild-type GENE SET (as determined by the in vitro immunoassay methodology described infra). These specific anti-mutant GENE SET antibodies may be used to detect the presence of GENE SET by measuring the immunospecific-binding by the anti-mutant GENE SET antibodies and, optionally, the lack of immunospecific-binding by the anti-(wild-type) GENE SET antibodies Moreover, GENE SET proteins possessing deletion or insertion mutations may be detected by either an increase or decrease in protein size by methodologies which include, but are not limited to, for example, but not limited to, Western blot analysis using an anti-GENE SET antibody which recognizes both the mutant and wild-type GENE SET.

[0098] Immunoassays which may be utilized in the practice of the present invention include, but are not limited to, competitive and non-competitive assay systems using techniques such as Western blots, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays(ELISA), “sandwich” immunoassays, immunoprecipitation assays, precipitation reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein-A immunoassays, and the like.

[0099] In a specific embodiment of the present invention, methods of diagnosis, prognosis and screening are disclosed and utilize the detection of mutant GENE SET alleles in genomic DNA or mRNA (i.e., genetic screening). These aforementioned mutant GENE SET alleles may be detected by any method known in the art for detecting mutations in genomic DNA including, but not limited to: DNA hybridization methods (e.g. Southern Blotting), RFLP mapping, PCR-based amplification methodologies, and the like, may be used with nucleic acid probes which are complementary to both the mutation and the corresponding position within the wild-type GENE SET sequence.

[0100] In a preferred embodiment, allele-specific PCR (ASP) may be used to detect mutant GENE SET alleles. In the ASP methodology, a target DNA is, preferentially, amplified only if it is completely complementary to the 3′-terminus of a specific PCR amplification primer. The 3′-terminus of the primer is designed so as to terminate at, or within one or two nucleotides of a known mutation site within the GENE SET gene (target DNA) to which it possesses a complementary sequence. Under the appropriate reaction conditions, the target DNA is not amplified if there is a single nucleotide mismatch (e.g., a nucleotide substitution caused by a mutation) or a small deletion or insertion, at the 3′-terminus of the primer. See e.g., Okayama, et al, 1989. J Lab. Clin. Med 114:105-113; Sommer, et al., 1992. BioTechniques 12:82-87). Accordingly, ASP may be utilized to detect either the presence or absence of (at least) a single nucleotide mismatch between the primer sequence (which is complementary to the pre-selected GENE SET target sequence) and a nucleic acid within the sample. Amplification of the GENE SET sequence is indicative of a lack of even a single mismatched nucleotide.

[0101] Additionally, where the mutant comprises a deletion or insertion mutation, mutant GENE SET alleles may be detected by screening for an increase or decrease in the length of the GENE SET nucleic acid sequence, or portion thereof. The increase or decrease in length may be detected by any method known within the art for measuring the length of nucleic acids, including, but not limited to, amplification of a specific fragment of the GENE SET sequence from the subject to be diagnosed or screened and from a standard or control sample and comparison of the length of the fragments by any size fractionation method (e.g., denaturing polyacrylamide gel electrophoresis.

[0102] Additionally, kits for diagnostic or screening use are also disclosed herein which comprise, in one or more containers, an anti-GENE SET antibody or anti-GENE SET mutant antibody and, optionally, a labeled binding partner to the antibody. Alternatively, the anti-GENE SET antibody or anti-GENE SET mutant antibody may be detectably-labeled (e.g., with a chemiluminescent, enzymatic, fluorescent, or radioactive moiety). In another embodiment, a kit is provided which comprises, in one or more containers, a nucleic acid probe which is capable of specifically-hybridizing to GENE SET RNA or, preferably, to mutant GENE SET RNA. In a specific embodiment of the present invention, a kit is provided which comprises, in one or more containers, a pair of primers (e.g., each in the size range of 6-30 nucleotides) which are capable of priming amplification reactions, under appropriate reaction conditions, of at least a portion of a GENE SET nucleic acid. These amplification reactions include, but are not limited to, polymerase chain reaction (PCR); ligase chain reaction; Qβ replicase, cyclic probe reaction or other amplification methods known within the art. A kit may, optionally, further comprise, in a container, a predetermined concentration of a purified GENE SET protein or nucleic acid, for use as a standard or control.

[0103] (5) Assays for Modulators of GENE SET Proteins and Nucleic Acids

[0104] A variety of methodologies are available within the art for assaying the activity of GENE SET proteins (and derivatives, analogs, fragments and homologs of GENE SET proteins), as well as for the nucleic acids encoding the GENE SET proteins (and derivatives, analogs, fragments and homologs thereof). Methods are also available for the screening of putative GENE SET modulators (e.g., GENE SET agonists, antagonists and inhibitors). Such modulators of GENE SET activity include, but are not limited to, GENE SET anti-sense nucleic acids, anti-GENE SET antibodies, and competitive inhibitors of GENE SET proteins for binding to the GENE SET protein receptors.

[0105] The activity of the GENE SET proteins (and derivatives, fragments, analogs and homologs of GENE SET proteins), the nucleic acids encoding these GENE SET proteins (and derivatives, fragments, analogs and homologs thereof) and putative modulators of GENE SET protein activity may also be ascertained in vivo. For example, infusion of GENE SET proteins in humans causes significant increases in cGMP levels in plasma and urine. See e.g., Vesely, et al., 1995. Am. J Med Sci. 310:143-149; Vesely, et al., 1996. Metabolism: Clin & Exp. 45:315-319. Administration of GENE SET proteins to humans also elicits significant diuresis and reduction in blood pressure (see e.g., Vesely, et al., 1996. Life Sciences 59:243-254); similar effects have also been observed in rodents (see e.g., Garcia, et al., 1989. Hypertension 13:567-574). In accord, the mutant GENE SET proteins and nucleic acids (and derivatives, analogs, fragments and homologs thereof) and putative GENE SET modulators may be assayed by the administration of a “test compound” to an animal, preferably a non-human test animal, followed by the measurement of the one or more of the physiological parameters described above (e.g., cGMP levels in urine and/or plasma, diuretic effect, decrease in blood pressure, and the like).

[0106] Another embodiment of the present invention discloses a methodology for screening a GENE SET mutant for a change in activity comprising (i) administering the GENE SET mutant to a test animal prone to stroke, hypertension, diabetes or obesity and (ii) measuring of stroke latency within the test animal in which stroke latency is indicative of GENE SET activity. In a specific embodiment, a recombinant test animal, which expresses a GENE SET transgene or expresses a member of the GENE SET under the control of a promoter which is not the native GENE SET gene promoter at an increased level relative to a wild-type test animal, is used to screen the GENE SET for a change in GENE SET activity.

[0107] In another embodiment of the present invention, a method for screening for a modulator of GENE SET activity, or of latency or predisposition to stroke, is provided which comprises measuring stroke latency within a stroke-prone animal that recombinantly expresses a putative modulator of GENE SET activity, in which a change in stroke latency relative to an analogous stroke-prone animal which does not recombinantly-express the putative modulator, indicates that the putative modulator possesses the ability to modulate GENE SET activity, or latency or predisposition to stroke.

[0108] In yet another embodiment, a method is provided for screening an GENE SET mutant for an effect on latency or predisposition to stroke comprising measuring stroke latency within a stroke-prone animal which recombinantly-expresses a GENE SET mutant, in which a change in stroke latency relative to an analogous stroke-prone animal which does not recombinantly express the GENE SET mutant indicates that the GENE SET mutant has an effect on latency or predisposition to stroke, hypertension, diabetes or obesity. In a preferred embodiment, a GENE SET mutant is screened for an increase in stroke latency or a decrease in predisposition to stroke.

[0109] (6) Pharmaceutical Compositions and Therapeutics

[0110] The present invention discloses methods of treatment and prophylaxis by administering to a subject of an effective amount of a Therapeutic of the invention. In a preferred embodiment, the Therapeutic is substantially-purified. The subject is preferably an animal which, preferably, is a mammal and most preferably human.

[0111] Formulations and methods of administration which may be employed when the Therapeutic comprises a nucleic acid are described in Sections 3(a) and 3(c), supra; whereas additional appropriate formulations and routes of administration may be selected from among those described infra.

[0112] Numerous types of pharmaceutical composition delivery systems are well-known within the art and may be utilized to administer a Therapeutic of present the invention. These aforementioned delivery systems include, but are not limited to: (i) encapsulation in liposomes, microparticles and microcapsules; (ii) recombinant cells capable of expressing the Therapeutic; (iii) receptor-mediated endocytosis (see e.g., Wu & Wu, 1987. J Biol. Chem. 262:4429-4432); (iv) construction of a Therapeutic nucleic acid as part of a retroviral or other vector, and the like. Methods of administration/introduction include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The Therapeutic may be administered by any convenient route, for example by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the Therapeutic of the present invention into the central nervous system by any suitable route (e.g., intraventricular and intrathecal injection). Intraventricular injection may be facilitated by the use of an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir Pulmonary administration may also be employed (e.g., by use of an inhaler or nebulizer) and formulation with an aerosolizing agent.

[0113] In a specific embodiment of the present invention, it may be desirable to administer the Therapeutic of the present invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application (e.g., in conjunction with a wound dressing after surgery), by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers.

[0114] In another specific embodiment of the present invention, the Therapeutic may be delivered in a vesicle, in particular a liposome. See e.g., Langer, 1990. Science 249:1527-1533. In yet another specific embodiment, the Therapeutic may be delivered via a controlled release system including, but not limited to: a pump (see e.g., Sefton, 1987. CRC Crit. Ref Biomed. Eng. 14:201) and polymeric materials (see e.g., Smolen & Ball, 1983. Controlled Drug Bioavailability, Drug Product Design and Performance (Wiley, New York, N.Y.). In addition, a controlled release system may be placed in proximity of the therapeutic target (e.g., the brain), thus requiring only a fraction of the total systemic dose. See e.g., Goodson, 1984. Medical Applications of Controlled Release, (Wiley, New York, N.Y.).

[0115] In a specific embodiment of the present invention where the Therapeutic is a nucleic acid encoding a protein-based Therapeutic, the nucleic acid may be administered in vivo to promote expression of its encoded protein, by constructing of the aforementioned protein as part of an appropriate nucleic acid expression vector, and administering the construct so that it becomes intracellular by methodologies which include, but are not limited to: (i) use of a retroviral vector (see e.g., U.S. Pat. No. 4,980,286); (ii) use direct injection; (iii) use of microparticle bombardment (e.g., a gene gun; Biolistic, DuPont); (iv) coating with lipids or cell-surface receptors or transfecting agents; (v) administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see e.g., Joliot, et al, 1991. Proc. Natl. Acad Sci. USA 88:1864-1868) and the like.

[0116] In an alternate embodiment of the present invention, a nucleic acid-based Therapeutic may be introduced intracellularly and incorporated by homologous recombination within host cell DNA for expression.

[0117] The present invention also discloses pharmaceutical compositions. Such compositions comprise a therapeutically-effective amount of a Therapeutic within a pharmaceutically-acceptable carrier. In a specific embodiment, the term “pharmaceutically acceptable,” as utilized herein, is defined as the composition being approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopera for use in animals and, more particularly, in humans. The term “carrier,” as utilized herein refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers include, but are not limited to: sterile liquids (e.g., water, physiological saline and the like) and oils (e.g., oils of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like). Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Additionally, saline solutions and aqueous dextrose and glycerol solutions may also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are described in Martin, 1965. Remington's Pharmaceutical Sciences. Such compositions will contain a therapeutically-effective amount of the Therapeutic, preferably in purified form and, most preferably, in a substantially-purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation should be suited to the mode of administration.

[0118] In a preferred embodiment of the present invention, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water-free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

[0119] The Therapeutics of the present invention may be formulated with pharmaceutically-acceptable salts including those derived from hydrochloric, phosphoric, acetic, etc., and those formed with free carboxyl groups such as those derived from sodium, potassium, calcium, ferric hydroxides, isopropylamine, triethylarnine, 2-ethylamino ethanol, histidine, procaine, etc.

[0120] The amount of the Therapeutic of the present invention which will be effective in the treatment of a particular disorder or condition will be dependent upon the exact nature of the disorder or condition, and can be quantitatively-determined by standard clinical techniques. In addition, in vitro assays may (optionally) be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. However, suitable dosage ranges for intravenous administration are generally about 20-500 μg of active compound per kilogram (kg) body weight. Suitable dosage ranges for intranasal administration are generally about 0.01 pg/kg body weight to 1 mg/kg body weight. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Suppositories generally contain active ingredient in the range of 0.5% to 10% by weight; oral formulations preferably contain 10% to 95% active ingredient.

[0121] The present invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s), a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0122] (7) Animal Models

[0123] The present invention discloses animal models. In one embodiment, animal models for stroke, hypertension, diabetes or obesity are provided. Transgenic animals may be bred or produced through molecular-biological means, which over-express or under-express one or more of the GENE SET genes (e.g., by introducing a member or members of the GENE SET gene under the control of a heterologous promoter or a promoter which facilitates the expression of GENE SET proteins and/or nucleic acids in tissues which do not normally express GENE SET components. Additionally, “knockout” mice may be initially produced by promoting homologous recombination between a GENE SET gene in its chromosome and an exogenous GENE SET gene that has been rendered biologically inactive, preferably by insertion of a heterologous sequence (e.g., an antibiotic resistance gene) or by non-homologous recombination.

[0124] In a preferred embodiment of the present invention, introduction of heterologous DNA is carried out by transforming embryo-derived stem (ES) cells with a vector containing the insertionally-inactivated GENE SET gene or a GENE SET gene which is under the control of a heterologous promoter, followed by injecting the ES cells into a blastocyst and implanting the blastocyst into a “foster mother” animal. Accordingly, the resulting mice are chimeric animals (“knockout animal” or “transgenic animal”) in which an GENE SET gene has been inactivated or overexpressed or misexpressed (see e.g., Capecchi, 1989. Science 244:1288-1292). The chimeric animal can then be bred to produce additional knockout or transgenic animals. Such chimeric/transgenic animals include, but are not limited to, mice, hamsters, sheep, pigs, cattle, etc., and are, preferably, non-human mammals. Transgenic and knockout animals can also be made in D. melanogaster, C. elegans, and the like, by methods which are commonly-known within the art.

[0125] Another embodiment of the present invention provides a recombinant non-human animal containing a mutant GENE SET gene, under the control of a promoter which is not the native GENE SET gene promoter, in which the mutant GENE SET gene encodes a mutant GENE SET which increases latency to stroke. Yet another embodiment discloses a recombinant non-human animal that is the product of a process comprising introducing a nucleic acid into the non-human animal, or an ancestor thereof, said nucleic acid comprising a mutant GENE SET gene sequence.

[0126] (8) Specific Examples

[0127] Heart, brain, fat, liver and kidney tissue from spontaneously hypertensive rats (SHR), stroke-prone SHR (SHR-SP) and control Wistar Kyoto rats (WKY) were analyzed by the GeneCalling® methodology (see PCT Publication WO 97/15690) to facilitate the identification and characterization of genes which are differentially-expressed in the SHR and SHR-SP rats, as compared to the control WKY animals.

[0128] (A) Materials and Methodologies

[0129] (i) Isolation of Total Cellular RNA and Polv(A)⁺ mRNA

[0130] SHR, SHR-SP and WKY rats were maintained on normal rat chow (Purina) and water ad libitum. Thirteen week old rats were sacrificed and the hearts, liver, fat, kidney and brain tissues were removed and quick-frozen in liquid nitrogen immediately following dissection. The whole organs were stored at −70° C. for subsequent processing.

[0131] Total cellular RNA was extracted from 5 mg of heart, liver, fat, kidney, or brain tissue by initially grinding the tissue into a fine powder in liquid nitrogen. The powdered tissue was then transferred to a tube containing 500 μl Triazol Reagent® (Life Technologies; Gaithersburg, Md.) and was dispersed in the Triazol Reagent® using a Polytron homogenizer (Brinkman Instruments; Westbury, N.Y.). See e.g., Chomszynski, et al., 1987. Annal. Biochem. 162 156-159; Chomszynski, et al., 1993. BioTechniques 15:532-533, 536-537. The total cellular RNA fraction was then extracted with 50 μl BCP (1-bromo-3-chloropropane; Molecular Research; Cincinnati, Ohio) to facilitate phase separation. The extraction mixture was centrifuged for 15 minutes at 4° C. at 12,000×G, and the aqueous phase was removed and transferred to a fresh tube. The RNA was then precipitated with 0.5 volume of isopropanol per original volume of Triazol Reagent® used, and the sample was re-centrifuged at room temperature for 10 minutes at 12,000×G. The supernatant was then discarded, the pellet washed with 70% ethanol and re-centrifuged at room temperature for 5 minutes at 12,000×G. Finally the 70% ethanol was removed and the centrifuge tube was inverted and let stand to dry in this position. The resulting RNA pellet was re-suspended in 100 μl water (i.e., 1 μl/mg of original tissue weight) and heated to 55° C. until completely dissolved. The final concentration of total cellular RNA was quantitated by fluorometry with OliGreen® (Molecular Probes; Eugene, Oreg.). In addition, the quality of the total cellular RNA was determined by both spectrophotometry and formaldehyde agarose gel electrophoresis.

[0132] Poly(A)⁺ RNA was prepared from 100 μg of total cellular RNA by use of affinity chromatography with oligo(dT) magnetic beads (PerSeptive; Cambridge, Ma.) or with the Dynabeads mRNA Direct Kit® (Dynal; Oslo, Norway) as directed by the manufacturer. The Poly(A)⁺ RNA was harvested in a small volume of sterile water, and the final yield quantified by OD₂₆₀ measurement and fluorometry with OliGreen® (Molecular Probes; Eugene. OR). The Poly(A)⁺ RNA was stored at −20° C. for subsequent utilization in cDNA synthesis and GeneCalling® protocols.

[0133] (ii) cDNA Synthesis

[0134] Prior to cDNA synthesis, each of the Poly(A)⁺ RNA samples from the aforementioned tissues were treated with DNase to remove endogenous, contaminating DNA. 28 μl of 5> reverse transcriptase buffer (Life Technologies; Gaithersburg, Md.), 10 μl 0.1 M DTT, 5 units RNAguard® (Pharmacia Biotech, Upsala, Sweden) per 100 mg tissue and 1 unit RNase-free DNase 1 (Pharmacia Biotech) per 100 mg tissue, were added to the re-suspended RNA samples. The reaction mixtures were then incubated at 37° C. for 20 minutes. The total RNA concentration was quantified by measuring OD260 of a 100-fold dilution and the samples were stored at −20° C.

[0135] cDNA was synthesized from the Poly(A)⁺ RNA as follows: the Poly(A)⁺ RNA isolated from each of the aforementioned tissues was mixed with 50 ng random hexamer primers (50 ng/μl) in 10 μl of water. The mixtures were heated to 70° C. for 10 minutes, quick-chilled in an ice-water slurry, and kept on ice for 1-2 min. The condensates were then collected by centrifugation in a microfuge for approximately 10 seconds.

[0136] The first-strand synthesis was performed by adding to the reaction mixtures: 4 μl 5×first-strand buffer (from a BRL cDNA Synthesis Kit; Grand Island, N.Y.), 2 μl 100 mM DTT, 1 μl 10 mM dNTP mix, and 2 μl water to each of the primer-annealed Poly(A)⁺ RNA. Alternately, 200 pmols of oligo(dT)₂₅V (V=A, C or G) was utilized as a primer in the first-strand synthesis reactions. The reaction mixtures were then incubated at 37° C. for 2 minuets, followed by the addition of 1 μl of Superscript II® reverse transcriptase (BRL) and the reactions were incubated at 37° C. for 1 hour.

[0137] Second-strand cDNA synthesis was then performed. The samples were placed on ice and to each of the first-strand reaction mixture was added: 30 μl of 5×second-strand buffer, 90 μl of cold water, 3 μl of 10 mM DNTP, 1 μL (10 units) of E. coli DNA ligase (BRL), 4 μl (40 units) of E. coli DNA polymerase I (BRL), and 1 μl (3.5 units) of E. coli RNaseH (BRL) and the reaction mixtures were incubated for 2 hours at 16° C. The resulting double-stranded cDNA was then incubated with 2 μl of T₄ DNA polymerase (5 units) at 16° C. for 5 minutes.

[0138] The resulting cDNA was then dephosphorylated with Arctic Shrimp Alkaline Phosphatase (“SAP”; USB; St. Louis, Mich.) by adding to each reaction mixture: 20 μl 10×SAP buffer, 25 μl of water, and 5 μl (5 units) of SAP. The reactions were incubated at 37° C. for 30 minutes.

[0139] The cDNA was extracted with phenol/chloroform (50:50 v/v), chloroform/isoamyl alcohol (99:1 v/v) and precipitated from the aqueous phase by the addition of NaOAc pH 5.0 to 0.3 M, 20 μg glycogen, and 2.5 volumes of ethanol followed by incubation at −20° C. for 10 minuets. The cDNA was collected by centrifugation at 14,000×g for 10 minuets. The supernatant was then aspirated and the resulting cDNA pellet was washed with 75% ethanol. resuspended in TE buffer (pH 7.0) and the yield of cDNA was estimated using fluorometry with Picogreen® (Molecular Probes; Eugene, Oreg.).

[0140] (iii) GeneCalling® Methodology

[0141] The GeneCalling® methodology is comprised of a 3-step process which involves cDNA fragmentation, tagging and amplification. Fragmentation was achieved by restriction enzyme digestions in a 50 μl reaction mix containing 5 units of each restriction enzyme, 1 ng of double-stranded cDNA and 5 μl of the appropriate 1×restriction endonuclease buffer. Analysis of all mRNAs was achieved by performing 80 separate sets of cDNA fragmentation reactions, each with a different pair of restriction enzymes. Tagging was achieved by ligation of amplification cassettes with ends compatible to the 5′- and 3-termini of the cDNA fragments. A FAM label was incorporated onto the 5′-terminus of one of the PCR primers. Incubation of the ligation reaction was performed at 16° C. for 1 hour in 10 mM ATP, 2.5% PEG, 10 units T4 DNA ligase and 1×ligase buffer.

[0142] PCR amplification was performed by the addition of the following reagents to each of the reaction tubes: 2 μl 10 mM dNTP, 5 μl 10×TB buffer (500 mM Tris, 160 mM (NH₄)₂SO₄, 20 mM MgCl₂, pH 9.15), 0.25 μl KlenTaq® (Clontech Advantage):PFU® (Stratagene, La Jolla Calif.) (16:1) and 32.75 μl H₂O. Twenty (20) cycles of amplification (30 seconds at 96° C., 1 minute at 57° C., 2 minutes at 72° C.), followed by 10 minutes at 72° C., were performed in a PTC-100 Thermal Cycler equipped with a mechanized lid (MJ Research; Watertown, Ma.).

[0143] Post-PCR amplification product purification was performed using streptavidin magnetic beads (MPG® Beads; CPG, Lincoln Park, N.J.). After washing the beads twice with buffer 1 (3 M NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 7.5), 20 μl of buffer 1 was mixed with the PCR product for 10 minutes at room temperature, separated with a magnet, and washed once with buffer 2 (10 mM Tris, 1 mM EDTA, pH 8.0). The beads were then dried and resuspended in 3 μl of buffer 3 (80% (v/v) formamide, 4 mM EDTA, 5% TAMRA- or ROX-tagged molecular size standard (PE-Applied Biosystems, Foster City Calif.). Following denaturation at 96° C. for 3 minutes, samples were then loaded onto 5% polyacrylamide, 6M urea, 0.5×TBE ultrathin gels and electrophoresed on a proprietary Niagara® gel electrophoresis system. PCR products were visualized by virtue of the fluorescent FAM label at the 5′ end of one of the PCR primers, which ensures that all detected fragments have been digested by both enzymes.

[0144] The primary components of the Niagara® gel electrophoresis system are an interchangeable horizontal ultrathin gel cassette mounted in a platform employing stationary laser excitation and a multi-color CCD imaging system. Each gel cassette may be loaded with a total of 48 lanes (4 cycles of 12 wide) directly from a 96-well plate using a Beckman Biomek 2000® robotic arm (Beckman, Sunnyvale, Calif.). The Niagara electrophoresis system has the advantage of high throughput, with separation of fragments between 30 and 450 bases in 45 minutes.

[0145] (iv) Niagara® Gel Interpretation

[0146] The output from the Niagara® gel electrophoresis system was processed using the Java-based, internet-ready Open Genome Initiative (OGI) software suite. Gels images were initially visually checked and tracked. Each lane contained the FAM-labeled products of a single GeneCalling® reaction plus a molecular weight “sizing-ladder” spanning the range from 50 to 500 bp. The ladder peaks provided a correlation between camera frames (collected at 1 Hz) and DNA fragment size in base pairs (bp). Following tracking, the lanes were extracted and the peaks in the sizing ladder were ascertained. Linear interpolation between the ladder peaks was utilized to convert the fluorescence traces from frames to base pairs. A final quality control (QC) step checked for various anomalies (e g, low signal-to-noise ratio, poor peak resolution, missing ladder peaks, and lane-to-lane sample bleeding). Data which passed all of the aforementioned criteria were submitted as point-by-point length versus amplitude addresses to an Oracle 8 database for subsequent difference identification.

[0147] (v) Difference Identification

[0148] For each restriction enzyme pair (subsequence) comprising each sample set, a composite trace was calculated. This composite trace calculation entailed compiling all of the individual sample replicates, followed by application of a scaling algorithm for best-fit to normalize the traces of the experimental set versus that of the control set. The scaled traces were then compared on a point-by-point basis to define areas of amplitude difference which meet the minimum, pre-specified threshold for a statistically-significant difference. Once a region of difference was characterized, the local maximum for the corresponding traces of each set was identified. All difference peaks were stored as unique database addresses in the specified expression difference analysis.

[0149] (vi) Northern Blot Analysis

[0150] 1 μg of Poly (A)⁺ RNA from 3 animals of each genotype was electrophoresed in agarose/formaldehyde gels, blotted to PVD-nylon filters and probed with fill-in oligonucleotides labeled with ³²P-dCTP. The hybridization was quantitated with a storage phosphor imaging plate using the Fuji BAS2000®. Blots were stripped and re-probed for GAPDH to normalize gene expression levels. Induction levels are expressed as the ratio of average normalized hybridization signals.

[0151] (vii) Radiation Hybrid Mapping

[0152] A commercially-available, rat T55 radiation hybrid panel (Research Genetics; Huntsville, Ala.), consisting of 106 individual hybrids was utilized in this analysis. It was determined empirically, that hybrid samples 1, 20, 35, 38, 60 and 90 had very low retention when compared to the other samples in the panel. In addition, a total of 94 rat hybrid (RH) samples was utilized, in order to efficiently perform PCR in a 96-well format (94 RH samples, plus negative and positive control). Accordingly, RH samples 1-100 from the T55 radiation hybrid panel, excluding the 6 low retention RH samples, previously discussed.

[0153] MapPairs® simple sequence repeat (SSR) markers (Research Genetics) were utilized. All markers were run in duplicate and evaluated/scored as a pair. RH templates were distributed into 384 well PCR plates (MJ Research) at 20 ng/well using a Tecan Genesis 100® pipetting robot, and allowed to desiccate. PCR reactions were performed in 5 μl total volumes using the following concentrations of reagents: 0.5 μM each primer, 200 μM dNTPs, 1×PC2 buffer (50 mM Tris-HCl pH 9.1, 16 mM ammonium sulfate, 3.5 mM MgCl₂, 150 μg/ml BSA, 1×Rediload (Research Genetics) and 0.25U KlenTaq® (Clonetech Advantage). PCR amplification reaction conditions (Thermocycle) were as follows: initial 3 minute denaturation at 94° C.; subsequent denaturation at 94° C. for 30 seconds; initial annealing temperature of 65° C. for 30 seconds; elongation at 68° C. for 30 seconds; second cycle annealing temperature of 63° C. for 30 seconds; all subsequent cycles, annealing temperature of 60° C. for a total of 35 cycles.

[0154] PCR products were then subjected to electrophoresis through a 3% agarose (BRL) gel using 1×TBE buffer, for 30 min at 200V. Gel images were documented using an Alpha Innotech 950® imaging system.

[0155] (B) Experimental Results

[0156] (i) Identification of Differentially-expressed Genes between the SHR-SP, SHR and WKY by GeneCalling

[0157] GeneCalling® reactions were performed on whole organs from adipose, kidney, heart, brain and liver as previously described, and gene expression profiles were compared between the SHR-SP and SHR and between the SHR and WKY animals.

[0158] An average of 20,000 GeneCalling® fragments were measured for relative abundance, yielding between 0.3% and 1.4% differences in gene expression. The results of this analysis are shown in Table 1. The SHR vs. WKY comparisons gave about 3-fold more differences than the SHR-SP vs. SHR comparisons, which is not surprising since the SHR-SP diverged from the SHR more recently than the SHR diverged from the WKY. By percentage, the most changes in gene expression were seen in the liver of the SHR relative to the WKY (1.4%), whereas the fewest changes were seen in the heart of the SHR-SP relative to the SHR (0.3%).

[0159] On average, three GeneCalling® fragments per gene were measured for relative abundance, allowing fault-tolerance in the event of sequence variation between the strains being compared. The relative abundance of each GeneCalling® fragment is illustrated in FIG. 1. Modulation was reported in fold-increase or fold-decrease in each tissue measured, with positive modulation (fold-increase) indicating increased mRNA abundance in the SHR (Table 2) or SHR-SP (Table 3) GeneCalling® samples.

[0160] Comparison of the SHR and WKY sanples, resulted in the finding of a total of 48 differentially-expressed genes with identity or significant similarity to sequences which had been previously reported to GenBank. This figure accounted for approximately one-half the total number of gene expression differences (Table 2, FIG. 2). Interestingly, two genes were found to be modulated within all 5 tissues studied, indicating organism-wide alterations in gene expression which may link the phenotypes seen in the different organs.

[0161] Comparison of the SHR-SP and SHR samples, resulted in the finding of 14 differential-expressed genes with significant similarity to sequences which had been previously reported to GenBank (Table 3, FIG. 2), with an average of 2.7 fragments per gene and one gene modulated across all 5 tissues.

[0162] (ii) Mapping of Differentially-Expressed Genes

[0163] Differentially-expressed and previously unmapped genes of interest were placed on the physical map utilizing a radiation hybrid panel. Upon genotyping, map positions were constructed using RHMAPPER® computer program. Examples of mapped genes are shown in FIG. 3, Table 2, column 7 and Table 3, column 4. The map locations of the differentially-expressed genes were compared to quantitative trait loci (QTL) previously-reported in the literature and/or reported to GenBank. Of the 26 differentially-expressed genes whose map locations have been determined, six of the aforementioned genes mapped to within previously described QTL (FIG. 3, Table 1, Table 2). These six genes, in toto, as utilized within the scope of the present invention, were designated the GENE SET genes.

[0164] Specifically, the six differentially-expressed genes were mapped to the following chromosomal positions: (i) kynurenine aminotransferase mapped to chromosome 3 between D3rat100 and D3kyo2; (ii) CD36 mapped to chromosome 4 between D4rat5 and D4rat7; (iii) SGLT2 maps near the SA locus on chromosome 1; (iv) aldolase A maps near the SA locus on chromosome 1 and (v) both α cardiac myosin and α-tubulin are part of the RT complex on chromosome 20. In addition, the atrial natriuretic peptide (ANP) was found to map between Elaiil and D5mgh16.

[0165] (iii) Detection of Mutated Genes Within the QTL

[0166] Sequence variations between the SHR-SP, SHR and WKY rodent strains were detected by direct sequencing of cDNAs which derived from PCR-amplified cDNA initially synthesized from oligo(dT)-selected, Poly (A)⁺ RNA from the tissues analyzed for gene expression.

[0167] Amino acid substitutions were found in five of the six genes which were demonstrated to be differentially-expressed between the disease animal strains (i.e., SHR and SHP-SP) and the control strain (WKY) and which additionally mapped to QTL identified as contributing to the traits of interest in cross between the disease model and control.

[0168] Specifically, a conserved leucine (Leu) was found to be changed to glutamine (Glu) in the low-affinity, Na⁺-dependent glucose transporter SGLT2 (L638Q) which was found to map within a region which has been previously shown to contain a gene(s) contributing to blood pressure variation (FIG. 3). The amino acid sequence of the region possessing the amino acid substitution of the SGLT2 variant (L638Q) in SHR, WKY, human, rabbit and pig is shown in FIG. 4 [SEQ ID NO:1].

[0169] Kynurenine aminotransferase was demonstrated to possess an amino acid substitution which involves the changing of a specific charge at amino acid residue position 27 (E27G). Previously, this residue was found to be conserved across all known family members to the C elegans kynurenine aminotransferase homolog, and the mutated gene also mapped to a region shown to be involved in blood pressure regulation. The amino acid sequence of the region possessing the amino acid substitution of the kynurenine aminotransferase variant (E27G) in SHR, WKY, human and nematode is shown in FIG. 4 [SEQ ID NO:2].

[0170] Similarly, the fatty acid transport protein (FAT)/CD36 homolog was found to contain numerous amino acid substitutions and mapped to a region which was shown to be defective in the SHR, with regards to both glucose uptake and impaired fatty acid secretion. The amino acid sequence of the region possessing the amino acid substitution in amino acid residues 148-191 and 213-257 of the FAT/CD36 variant in SHR-SP, SHR, WKY and human is shown in FIG. 4 [SEQ ID NO:3] and [SEQ ID NO:4], respectively.

[0171] Aldolase A was demonstrated to map to the stroke predisposition locus on chromosome 1 and possessed a methionine (Met) to valine (Val) amino acid substitution near the protein's amino terminus. It should be noted that the amino acid sequence of aldolase A is extremely conserved throughout numerous genus and species. The amino acid sequence of the region possessing the amino acid substitution of the aldolase A variant in SHR-SP, SHR, WKY, mouse, human, seal, dog and rabbit is shown in FIG. 4 [SEQ ID NO:5].

[0172] The prepronatriodilatin gene, which encodes the atrial natriuretic peptide (ANP) was found to contain an altered glycine (Gly) amino acid residue in the SHR which is conserved across species, and mapped to a region which has been implicated in the etiology of both stroke and hypertension. See e.g., Rubattu, et al., 1996. Nat. Genet. 13(4):429-434. The amino acid sequence of the region possessing the amino acid substitution of the prepronatriodilatin variant in SHR-SP, SHR, WKY, human, pig and horse is shown in FIG. 4 [SEQ ID NO:6].

[0173] Similarly, the amino acid sequence of the region possessing the amino acid substitution of the α-cardiac myosin variant in SHR-SP, SHR, WKY, mouse and human is shown in FIG. 4 [SEQ ID NO:7] and the amino acid sequence of the region possessing the amino acid substitution of the α-tubulin variant in SHR, WKY, mouse, chicken, human and fluke is shown in FIG. 4 [SEQ ID NO:8].

[0174] (C) Physiological and Biochemical Significance of the Experimental Results

[0175] Presented herein is the first comprehensive organ survey of differential gene expression in a genetic disease animal model, coupled with a comprehensive mapping and mutation-detection strategy to facilitate the identification of the specific gene(s) involved directly and/or indirectly in complex disease phenotypes The present invention, for the first time, implicates many new genes and their respective pathways in the mechanisms of these complex diseases, and highlights those genes whose variants may directly cause the disease phenotypes. Using this strategy to define the overlap between differential gene expression in a disease versus normal model and the map location(s) of the disease trait(s) is a powerful way of rapidly identifying genes that cause disease.

[0176] A total of sixty known rat genes (or rat homologs of genes known in other species) were found to be differentially-expressed in the analysis of five tissues. Six of these genes mapped to within chromosomal regions which have been implicated in various disease traits, and a total of seven genes were shown to possess amino acid substitutions which may influence these aforementioned disease traits.

[0177] (i) Hypertension- and Obesity-Related Genes

[0178] The differential-expression and amino acid substitution of the L638Q variant of the low affinity sodium-dependent glucose transporter, SGLT2, suggests that this transporter may be directly involved in the SHR phenotype. Activating mutations affecting selectivity, stoichiometry or activation state may increase sodium reabsorption, leading to plasma volume expansion and concomitant hypertension. Similarly, increased glucose reabsorption through this transporter enzyme, might lead to increased plasma glucose. Accordingly, antagonists/blockers of sodium-glucose transporter activity are currently being developed for utilization in anti-diabetic applications. See e.g., Tsujihara, al, 1996. Chem. Pharm. Bull. (Tokyo) 44(6):1174-1180.

[0179] The identification of kynurenine aminotransferase variant E27G, may help explain the previous finding that the activity of this enzyme in the SHR brain is greatly reduced relative to activity in the WKY brain. See e.g., Kapoor, et al., 1994. Clin. Exp. Pharmacol. Physiol. 21(11):891-896. Kynurenine aminotransferase catalyzes the conversion of kynurenine to kynurenic acid, an excitatory amino acid receptor antagonist. This implicates the kynurenine pathway in blood pressure regulation and suggests the possibility that kynurenic acid may have anti-hypertensive applications. An associated increase in the expression of the water channel protein, aquaporin 3, suggests that increased water reabsorption, leading to plasma volume expansion, may be linked to anomalies in the kynurenine pathway. While aquaporin 2 is differentially-expressed in a congestive heart failure model (see e.g., Nielson, 1997. Proc. Natl. Acad. Sci. USA 94(10):5450-5455), aquaporin 3 is a thirst-responsive channel with a role in osmotically-driven water absorption across the collecting duct epithelium, which has no previous association with a disease state (see e.g., Ecelbarger, et al., 1995. Am. J Physiol. 269(5):F663-672.

[0180] Increased expression of 21-hydroxylase, the final enzyme in aldosterone synthesis which is mutated in patients with adrenal hyperplasia (see e.g., Jospe, et al., 1987. Biochem. Biophys. Res. Commun. 142(3):798-804), putatively suggests a transcriptionally-regulated mechanism of increased aldosterone production. Interestingly, 21-hydroxylase alteration has also recently been associated with obesity/dyslipidemia (see e.g., Cornean, et al., 1998. Arch. Dis. Child. 78(3):261-263), which may help to link these two features (i.e., obesity and hypertension) of human Metabolic Syndrome X.

[0181] (ii) Insulin Resistance-Related Genes

[0182] The tissue-wide decrease in the differential-expression of α-SNAP suggests an additional mechanism of insulin resistance in the SHR. Due to the fact that α-SNAP plays a key role in the translocation of the insulin-responsive glucose transporter GLUT4 to the cell surface (see e.g., Mastick, et al., 1997. Endocrinology 138(6):2391-2397), a significant decrease in the levels of the α-SNAP protein may lead to insulin resistance through a defective protein-trafficking or translocation mechanism.

[0183] The finding of numerous amino acid substitutions and coincident map location of the rat homologs of the fatty acid transport protein (FAT)/CD36, platelet glycoprotein IV and the class B scavenger receptor to a major locus of impaired fatty acid secretion, strongly suggests that this multi-functional transporter may be directly involved in glucose uptake and fatty acid secretion. Previously, this chromosome 4 locus was also demonstrated to be the only genetic determinant of impaired isoproterenol-mediated, non-esterified fatty acid secretion in the SHR (see e.g., Aitman, et al., 1997. Nat. Genet. 16(2):856-862). In addition, FAT/CD36 has been shown to bind and internalize oxidized, low density lipoprotein, bind thrombospondin and collagen 1, and when mutated in humans leads to a defect in platelet-collagen adhesion (see e.g., Frieda, et al., 1995. J Biol. Chem. 270(7):2981-2986; Rigotti, et al., 1995. J Biol. Chem. 270(27):16221-16224; Ibrahimi, et al., 1996. Proc. Natl. Acad. Sci. U.S.A 93(7):2646-2651). The association between the SHR CD36 allele and insulin resistance suggests further functionality of this receptor, and the finding of linkage of NIDDM to a potentially syntenic region of human 7q suggests that CD36 may play a causal role in insulin resistance in humans. Coincidentally, the SHR-SP version of CD36 differs from the SHR version and maps near the chromosome 4 stroke protective locus (see e.g., Rubattu, et al., 1996. Nat. Genet. 13(4):429-434), suggesting the possibility of its involvement in the stroke phenotype as well.

[0184] Increased expression of the cardiac isoform of fatty acid binding protein (FABP) in the SHR adipocytes suggests a role for this member the FABP family in insulin resistance. Variants in the intestinal and adipocyte FABPs have been linked to obesity, dyslipidemia and insulin resistance (see e.g., Hotamisligil, et al., 1996. Science 274:1377-1379; Baier, et al., 1995. J Clin. Invest. 95(3):1281-1287). While the cDNA sequence of this gene was identical in the SHR and WKY rats, the differing levels of mRNA detected may affect protein levels contributing to the phenotype.

[0185] (iii) Stroke Predisposition-Related Genes

[0186] The discovery of the differential expression of a novel variant of prepronatriodilatin, which was mapped to a region associated with an increased stroke latency period (see e.g., Rubattu, et al, 1996. Nat. Genet. 13(4):429-434) and with increased infarct volume (see e.g, Jeffs, et al., 1997. Nat. Genet. 16(4):364-367), suggests a novel, blood pressure-independent role in stroke predisposition for the peptide hormones encoded by this gene. The fact that the products of this gene circulate in the bloodstream and may serve a protective role in stroke, serves to facilitate the development of pharmaceutical compounds for utilization in therapeutic intervention of stroke.

[0187] The finding of differential expression and amino acid substitution in the extremely conserved aldolase A gene, as well as its coincident location near a region of stroke predisposition, suggests that this enzyme (whose activity has long been known to be elevated in the sera of patients with cerebrovascular insult) may play a direct role in the onset of the cerebrovascular event. The amino acid residue which is substituted in the SHR-SP has been demonstrated to be completely conserved in every organisms from which it has been sequenced. including at least 12 mammals. While aldolase A is a well-characterized, glucose-induced glycolytic enzyme, it has been shown to bind α-tubulin, whose mRNA accumulates after transient ischemic brain insult (see e.g., Volker & Knull, 1997. Arch Biochem. Biophys. 338(2):237-243). Breakdown of the cytoskeleton has been proposed to be a central event in the evolution of ischemic brain damage. In addition, an amino acid substitution (S340T) was found in α-tubulin in the SHR and SHR-SP, relative to the amino acid sequence of the protein in both WKY control rodents and literature-reported sequences. This evidence suggests the possible involvement of aldolase A and α-tubulin in predisposition to vascular injury.

[0188] In addition, the demonstration of increased expression of cystatin C in the SHR-SP brain may play a significant role in the stroke phenotype, as mutations of this cysteine protease inhibitor, in humans, has been shown to cause cerebral hemmhorage (see e.g., Ghiso, et al., 1986. Proc. Natl. Acad. Sci. USA 83(9):2974-2978). While the human mutation does not alter the ability of cystatin C to inhibit cathepsin B, it does, nonetheless, permit dimerization and aggregation which leads to its subsequent deposition as amyloid. In the SHR-SP model, increased cystatin C synthesis may have an equally physiologically-deleterious effect on the cerebrovasculature by an accumulation of protein leading to aggregation.

[0189] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[0190] Various publication are cited herein, the disclosures of which are incorporated by reference in their entireties. TABLE 1 Differential Gene Expression Summary Between SHRSP, SHR and WKY Rats Genotype Comparison Tissue # Fragments # Diff. Expressed % Diff. Expressed SHR vs WKY Heart 11,600 108 0.9% SHR vs WKY Brain 36,500 384 1.1% SHR vs WKY Kidney 15,200 162 1.1% SHR vs WKY Adipose 28,300 207 0.7% SHR vs WKY Liver 27,100 382 1.4% SHR-SP vs SHR Heart 14,500 44 0.3% SHR-SP vs SHR Brain 35,700 150 0.4% SHR-SP vs SHR Kidney 7,500 39 0.5%

[0191] TABLE 2 Differential Gene Expression Between SHR and WKY Rats Δ in Δ in Δ in Δ in amino Gene heart Δ in brain Δ in kidney adipose liver Map acid y00979 Beta beta enolase +4.3 −6.3 −29.4 −4.1 −7.9 10  m15868 Prepronatriodilatin (ANF) +2.5 0 0 0 0  5* G99S x15939 Beta cardiac myosin heavy +8.5 0 0 0 0 11  chain 106433 c-HA-ras proto-oncogene +8.8 0 0 0 0 x90375 RT1.A1(N) alpha chain. +10.7 0 −6.7 0 0 20* Collagen11A2-like 0 +14.6 0 0 0 Mitogen activated protein (MAP) 0 +12.9 0 0 0 kinase-like Lysophospholipase-like 0 −3 −3.5 −7.3 0 m95763 GABA transporter GAT-3 0 −2.4 0 0 0 X Alpha enolase-like 0 −20.6 0 0 0 5 x60352 Alpha B-crystallin 0 +2.6 −2.6 +2.8 0 20  m54919 S100 protein beta subunit 0 −22.2 0 −20.0 0 7 m38179 3-beta-hydroxysteroid 0 0 +85.2 0 +2.6 dehydrogenase/delta-5-delta-4 isomerase x67156 (S)-2-hydroxy acid oxidase 0 0 −53.5 0 0 3 x89968 Alpha-soluble NSF attachment −3.2 −3.8 −23.6 −17.3 −4.7 protein s74029 Kynurenine aminotransferase 0 0 +22.4 0 0  3* E27G 137333 Flucose-6-phosphatase 0 0 −20.5 0 0 (G6Pase) Saccharopine dehydrogenase-like 0 −2.4 +15.9 0 0 Organic anion transport protein NKT- 0 0 −14.7 0 0 like Gluthathione-S-transferase-like 0 0 +13.6 0 0 Hemoglobinase-like (cysteine protease) 0 0 −7 0 0 af003944 Ovalbumin upstream 0 0 −6.9 0 0 promotoer beta nuclear receptor u29881 Na-dependent glucose 0 0 −6.7 0 0  1* L638Q transporter SGLT2 Dermatopontin-like 0 0 +6.2 +20.7 0 d17695 Water channel aquaporin 3 0 0 +5.4 0 0 (AQP3) 20 alpha-hydroxysteroid 0 0 +4.7 0 0 dehydrogenase-like Nicotinic receptor alpha 7 subunit-like 0 +5.5 +4.7 u56853 21-hydroxylase 0 0 +4.4 0 0 20  NAD(+)-dependent 15- 0 0 −4.1 hydroxyprostaglandin dehydrogenase- like 119658 Fatty acid transporter −14 0 0 −20.5 0  4* See. FIG. 3 (FAT/CD36) z24721 Superoxide dismutase 0 0 0 +6.2 0 11  m64755 Cysteine sulfunic acid 0 0 0 +3.2 0 decarboxylase x71127 Complenent protein C1q beta 0 0 0 +2.4 0 5 chain. j02773 Low molecular weight fatty 0 0 0 +2.4 0 acid binding protein z50144 Kynurenine/alpha- 0 0 0 −2.0 0 aminoadipate u51017 Kallistatin 0 0 0 0 +23.9 6 d00752 Contraspin-like protease 0 0 0 0 −17.4 6 inhibitor related protein Nuclear hormone receptor MB67-like +17.2 m18335 Cytochrome P450 0 0 0 0 −9.4 m22360 Plasma proteinase inhibitor 0 0 0 0 −7.3 alpha-1-inhibitor III group 3 m27440 Apolipoprotein B 0 0 0 0 −4.8 6 m95591 Hepatic squalene synthetase 0 0 0 0 −3.5 x52477 Pre-pro-complment C3 0 0 0 −2.2 −2.7 x05300 Ribophorin 1 0 0 0 0 −2.5 4 m17714 Insulin-like growth factor-I 0 0 0 0 −1.9 7 d90055 Peroxisomal 3-ketoacyl-CoA 0 0 0 0 +1.7 8 thiolase v01227 Alpha-tubulin 0 +15.6 0 0 0 5 S340T s76489 Estrogen sulfotransferase 0 0 0 −1.8 −2.6 1

[0192] TABLE 3 Differential Gene Expression Between SHSRP and SHR Rats Gene Δ in heart Δ in brain Δ in kidney Map Δ in amino acid m15868 Prepronatriodilatin (ANF) +2.5 −1.5 0  5* G99S 103294 Lipoprotein lipase +3.3 0 0 16  Alpha 2 actinin-like −3.7 0 0 Batroxostatin-like 0 +27.7 0 Sodium bicarbonate cotransporter (HNBC1)-like 0 +13.6 0 x16957 Cystatin C 0 +3.9 0 3 y00979 Beta beta enolase +4.7 +3.7 0 10  m12919 Aldolase A −51.7 −7.7 −9.7 1* M22V elF-4AII-like ND −9.6 ND SON3-like ND −4.6 ND x15938 Alpha cardiac myosin heavy chain +9.1 0 0 15/16 T10221 Immunoglobulin light chain-like +5.6 0 0 C. elegenas YK51G8.3-like +5.2 0 0 Sodium bicarbonate cotransporter-like ND +13.6 ND 

What is claimed is:
 1. Isolated mutant proteins selected from a group consisting of: SGLT2, kynurenine aminotransferase, FAT/CD36, aldolase A, prepronatriodilatin, α-cardiac myosin and α-tubulin; wherein the amino acid sequences of said mutant proteins possess one or more amino acid substitutions in comparison to the amino acid sequence of the corresponding native protein.
 2. The isolated mutant proteins of claim 1, wherein said mutant proteins are human proteins possessing the amino acid sequences depicted in FIG. 4 consisting of: SGLT2 [SEQ ID NO:1]; kynurenine aminotransferase [SEQ ID NO:2]; FAT/CD36 [SEQ ID NOS:3 AND 4]; aldolase A [SEQ ID NO:5]; prepronatriodilatin [SEQ ID NO:6]; α-cardiac myosin [SEQ ID NO:7] and α-tubulin [SEQ ID NO:8].
 3. The isolated mutant proteins of claim 1, wherein said mutant proteins are substantially-purified proteins.
 4. Antibodies which are specific for, and possess the ability to bind to said mutant proteins of claim
 1. 5. Isolated nucleic acid sequences encoding said mutant proteins of claim
 1. 6. Antibodies which are specific for, and possess the ability to bind to said nucleic acid sequences of claim
 5. 7. Isolated anti-sense nucleic acid derivatives of the nucleic acid sequences encoding said mutant proteins of claim
 1. 8. Antibodies which are specific for, and possess the ability to bind to said anti-sense nucleic acid derivatives of claim
 7. 9. The mutant proteins of claim 1, wherein said mutant proteins possess a longer biological half life in vivo, relative to the corresponding, native human proteins.
 10. A method of treating or preventing hypertension comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said mutant proteins of claim 1, sufficient to treat or prevent hypertension.
 11. A method of treating or preventing hypertension comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more antibodies specific for, and possessing the ability to bind to one or more of said mutant proteins of claim 1 sufficient to treat or prevent hypertension.
 12. A method of treating or preventing hypertension comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said nucleic acids of claim 5, sufficient to treat or prevent hypertension.
 13. A method of treating or preventing hypertension comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said anti-sense nucleic acid derivatives of claim 7, sufficient to treat or prevent hypertension.
 14. A method of treating or preventing diabetes and insulin resistivity comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said mutant proteins of claim 1, sufficient to treat or prevent diabetes and insulin resistivity.
 15. A method of treating or preventing diabetes and insulin resistivity comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more antibodies specific for, and possessing the ability to bind to one or more of said mutant proteins of claim 1 sufficient to treat or prevent diabetes and insulin resistivity.
 16. A method of treating or preventing diabetes and insulin resistivity comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said nucleic acids of claim 5, sufficient to treat or prevent diabetes and insulin resistivity.
 17. A method of treating or preventing diabetes and insulin resistivity comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said anti-sense nucleic acid derivatives of claim 7, sufficient to treat or prevent diabetes and insulin resistivity.
 18. A method of treating or preventing obesity and dyslipidemia comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said mutant proteins of claim 1, sufficient to treat or prevent obesity and dyslipidemia.
 19. A method of treating or preventing obesity and dyslipidemia comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more antibodies specific for, and possessing the ability to bind to one or more of said mutant proteins of claim 1 sufficient to treat or prevent obesity and dyslipidemia.
 20. A method of treating or preventing obesity and dyslipidemia comprising of administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said nucleic acids of claim 5, sufficient to treat or prevent obesity and dyslipidemia.
 21. A method of treating or preventing obesity and dyslipidemia comprising administering, to a subject in which such treatment or prevention is desired, an amount of one or more of said anti-sense nucleic acid derivatives of claim 7, sufficient to treat or prevent obesity and dyslipidemia.
 22. A method of treating or preventing or delaying stroke comprising of administering, to a subject in which such treatment or prevention or delay is desired, an amount of one or more of said mutant proteins of claim 1, sufficient to treat or prevent sufficient to treat or prevent or delay stroke.
 23. A method of treating or preventing or delaying stroke comprising of administering, to a subject in which such treatment or prevention or delay is desired, an amount of one or more antibodies specific for, and possessing the ability to bind to one or more of said mutant proteins of claim 1 sufficient to treat or prevent or delay stroke.
 24. A method of treating or preventing or delaying stroke comprising of administering, to a subject in which such treatment or prevention or delay is desired, an amount of one or more of said nucleic acids of claim 5, sufficient to treat or prevent sufficient to treat or prevent or delay stroke.
 25. A method of treating or preventing or delaying stroke comprising of administering, to a subject in which such treatment or prevention or delay is desired, an amount of one or more of said anti-sense nucleic acid derivatives of claim 7, sufficient to treat or prevent sufficient to treat or prevent or delay stroke.
 26. The method of claim 22, wherein said mutant prepronatriodilatin protein [SEQ ID NO:6] is administered to prevent stroke in a subject possessing one or more risk factors for stroke.
 27. The method of claim 22, wherein said stroke is ischemic stroke.
 28. The method of claim 22, wherein said mutant human prepronatriodilatin [SEQ ID NO:6] increases latency to stroke in stroke-prone rats fed a high salt diet.
 29. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of one or more of said mutant proteins of claim 1 and a pharmaceutically acceptable carrier.
 30. A kit, comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim
 29. 31. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of one or more of said nucleic acid of claim 5, and a pharmaceutically acceptable carrier.
 32. The pharmaceutical composition of claim 31, wherein said nucleic acid is a nucleic acid vector.
 33. A kit, comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim
 31. 34. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of one or more antibodies which are specific for, and possess the ability to bind to, one or more of said mutant proteins of claim 1, and a pharmaceutically acceptable carrier.
 35. A kit, comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim
 34. 36. A pharmaceutical composition comprising a therapeutically or prophylactically effective amount of one or more of said anti-sense nucleic acid derivatives of claim 7, and a pharmaceutically acceptable carrier.
 37. The pharmaceutical composition of claim 36, wherein said anti-sense nucleic acid derivative is a nucleic acid vector.
 38. A kit, comprising in one or more containers, a therapeutically or prophylactically effective amount of the pharmaceutical composition of claim
 36. 39. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant SGLT2 allele, the presence of said mutant SGLT2 allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 40. The method of claim 39 in which said mutant SGLT2 allele encodes a mutant SGLT2 having an amino acid substitution corresponding to the amino acid sequence of human SGLT2 as depicted in FIG. 4 (SEQ ID NO:1).
 41. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant kynurenine aminotransferase allele, the presence of said mutant kynurenine aminotransferase allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 42. The method of claim 41 in which said mutant kynurenine aminotransferase allele encodes a mutant kynurenine aminotransferase having an amino acid substitution corresponding to the amino acid sequence of human kynurenine aminotransferase as depicted in FIG. 4 (SEQ ID NO:2).
 43. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant FAT/CD36 allele, the presence of said mutant FAT/CD36 allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 44. The method of claim 43 in which said mutant FAT/CD36 allele encodes a mutant FAT/CD36 having an amino acid substitution corresponding to the amino acid sequence of human FAT/CD36 as depicted in FIG. 4 (SEQ ID NO:3 and NO:4).
 45. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant aldolase A allele, the presence of said mutant aldolase A allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 46. The method of claim 45 in which said mutant aldolase A allele encodes a mutant aldolase A having an amino acid substitution corresponding to the amino acid sequence of human aldolase A as depicted in FIG. 4 (SEQ ID NO:5).
 47. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant prepronatriodilatin allele, the presence of said mutant prepronatriodilatin allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 48. The method of claim 47 in which said mutant prepronatriodilatin allele encodes a mutant prepronatriodilatin having an amino acid substitution corresponding to the amino acid sequence of human prepronatriodilatin as depicted in FIG. 4 (SEQ ID NO:6).
 49. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant α-cardiac myosin allele, the presence of said mutant α-cardiac myosin allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 50. The method of claim 49 in which said mutant α-cardiac myosin allele encodes a mutant α-cardiac myosin having an amino acid substitution corresponding to the amino acid sequence of human α-cardiac myosin as depicted in FIG. 4 (SEQ ID NO:7).
 51. A method for screening for an allele protective against hypertension, diabetes, obesity and/or stroke in a subject comprising detecting a mutant α-tubulin allele, the presence of said mutant α-tubulin allele being indicative of an allele protective for hypertension, diabetes, obesity and/or stroke.
 52. The method of claim 51 in which said mutant α-tubulin allele encodes a mutant α-tubulin having an amino acid substitution corresponding to the amino acid sequence of human α-tubulin as depicted in FIG. 4 (SEQ ID NO:8).
 53. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant SGLT2 protein of claim 1 comprising: (a) administering a putative modulator of SGLT2 activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with SGLT2 activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates SGLT2 activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 54. The method of claim 53, wherein said test animal is a recombinant test animal which expresses an SGLT2 transgene or expresses SGLT2 under the control of a promoter which is not the native SGLT2 gene promoter at an increased level relative to a wild-type test animal.
 55. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant kynurenine aminotransferase protein of claim 1 comprising: (a) administering a putative modulator of kynurenine aminotransferase activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with kynurenine aminotransferase activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates kynurenine aminotransferase activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 56. The method of claim 55, wherein said test animal is a recombinant test animal which expresses a kynurenine aminotransferase transgene or expresses kynurenine aminotransferase under the control of a promoter which is not the native kynurenine aminotransferase gene promoter at an increased level relative to a wild-type test animal.
 57. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant FAT/CD36 protein of claim 1 comprising: (a) administering a putative modulator of FAT/CD36 activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with FAT/CD36 activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates FAT/CD36 activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 58. The method of claim 57, wherein said test animal is a recombinant test animal which expresses a FAT/CD36 transgene or expresses FAT/CD36 under the control of a promoter which is not the native FAT/CD36 gene promoter at an increased level relative to a wild-type test animal.
 59. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant aldolase A protein of claim 1 comprising: (a) administering a putative modulator of aldolase A activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with aldolase A activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates aldolase A activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 60. The method of claim 59, wherein said test animal is a recombinant test animal which expresses an aldolase A transgene or expresses aldolase A under the control of a promoter which is not the native aldolase A gene promoter at an increased level relative to a wild-type test animal.
 61. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant prepronatriodilatin protein of claim 1 comprising: (a) administering a putative modulator of prepronatriodilatin activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with prepronatriodilatin activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates prepronatriodilatin activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 62. The method of claim 61, wherein said test animal is a recombinant test animal which expresses a prepronatriodilatin transgene or expresses prepronatriodilatin under the control of a promoter which is not the native prepronatriodilatin gene promoter at an increased level relative to a wild-type test animal.
 63. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant α-cardiac myosin protein of claim 1 comprising: (a) administering a putative modulator of α-cardiac myosin activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with α-cardiac myosin activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates α-cardiac myosin activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 64. The method of claim 63, wherein said test animal is a recombinant test animal which expresses an α-cardiac myosin transgene or expresses α-cardiac myosin under the control of a promoter which is not the native α-cardiac myosin gene promoter at an increased level relative to a wild-type test animal.
 65. A method for screening for a modulator of the activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke of said mutant α-tubulin protein of claim 1 comprising: (a) administering a putative modulator of α-tubulin activity to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring one or more physiological parameters associated with α-tubulin activity, in which a change in said one or more parameters relative to an animal not administered the putative modulator indicates that the putative modulator modulates α-tubulin activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 66. The method of claim 65, wherein said test animal is a recombinant test animal which expresses an α-tubulin transgene or expresses α-tubulin under the control of a promoter which is not the native α-tubulin gene promoter at an increased level relative to a wild-type test animal.
 67. A method for screening a SGLT2 mutant for its SGLT2 activity comprising: (a) administering the SGLT2 mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring stroke latency in the test animal, in which stroke latency is indicative of SGLT2 activity.
 68. The method of claim 67 in which the test animal is a recombinant test animal which expresses an SGLT2 transgene or expresses SGLT2 under the control of a promoter which is not the native SGLT2 gene promoter at an increased level relative to a wild-type test animal.
 69. A method for screening a kynurenine aminotransferase mutant for its kynurenine aminotransferase activity comprising: (a) administering the kynurenine aminotransferase mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of kynurenine aminotransferase activity.
 70. The method of claim 69 in which the test animal is a recombinant test animal which expresses a kynurenine aminotransferase transgene or expresses kynurenine aminotransferase under the control of a promoter which is not the native kynurenine aminotransferase gene promoter at an increased level relative to a wild-type test animal.
 71. A method for screening a kynurenine aminotransferase mutant for its kynurenine aminotransferase activity comprising: (a) administering the kynurenine aminotransferase mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of kynurenine aminotransferase activity.
 72. The method of claim 71 in which the test animal is a recombinant test animal which expresses an kynurenine aminotransferase transgene or expresses kynurenine aminotransferase under the control of a promoter which is not the native kynurenine aminotransferase gene promoter at an increased level relative to a wild-type test animal.
 73. A method for screening a FAT/CD36 mutant for its kynurenine aminotransferase activity comprising: (a) administering the FAT/CD36 mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of FAT/CD36 activity.
 74. The method of claim 73 in which the test animal is a recombinant test animal which expresses a FAT/CD36 transgene or expresses FAT/CD36 under the control of a promoter which is not the native FAT/CD36 gene promoter at an increased level relative to a wild-type test animal.
 75. A method for screening a aldolase A mutant for its aldolase A activity comprising: (a) administering the aldolase A mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of aldolase A activity.
 76. The method of claim 75 in which the test animal is a recombinant test animal which expresses an aldolase A transgene or expresses aldolase A under the control of a promoter which is not the native aldolase A gene promoter at an increased level relative to a wild-type test animal.
 77. A method for screening a prepronatriodilatin mutant for its prepronatriodilatin activity comprising: (a) administering the prepronatriodilatin mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of prepronatriodilatin activity.
 78. The method of claim 77 in which the test animal is a recombinant test animal which expresses a prepronatriodilatin transgene or expresses prepronatriodilatin under the control of a promoter which is not the native prepronatriodilatin gene promoter at an increased level relative to a wild-type test animal.
 79. A method for screening an α-cardiac myosin mutant for its prepronatriodilatin activity comprising: (a) administering the α-cardiac myosin mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of α-cardiac myosin activity.
 80. The method of claim 79 in which the test animal is a recombinant test animal which expresses an α-cardiac myosin transgene or expresses α-cardiac myosin under the control of a promoter which is not the native α-cardiac myosin gene promoter at an increased level relative to a wild-type test animal.
 81. A method for screening an α-tubulin mutant for its prepronatriodilatin activity comprising: (a) administering the α-tubulin mutant to a test animal prone to hypertension, diabetes, obesity and/or stroke; and (b) measuring the latency of hypertension, diabetes, obesity and/or stroke in the test animal, wherein such latency is indicative of α-tubulin activity.
 82. The method of claim 81 in which the test animal is a recombinant test animal which expresses an α-tubulin transgene or expresses α-tubulin under the control of a promoter which is not the native α-tubulin gene promoter at an increased level relative to a wild-type test animal.
 83. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal, which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of SGLT2 activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate SGLT2 activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 84. The method of claim 83 in which said SGLT2 mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 85. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal, which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of kynurenine aminotransferase activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate kynurenine aminotransferase activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 86. The method of claim 85 in which said kynurenine aminotransferase mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 87. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal. which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of FAT/CD36 activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate FAT/CD36 activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 88. The method of claim 87 in which said FAT/CD36 mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 89. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal. which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of aldolase A activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate aldolase A activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 90. The method of claim 89 in which said aldolase A mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 91. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal, which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of prepronatriodilatin activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate prepronatriodilatin activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 92. The method of claim 91 in which said prepronatriodilatin mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 93. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal, which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of α-cardiac myosin activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate α-cardiac myosin activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 94. The method of claim 93 in which said α-cardiac myosin mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 95. A method for screening for a modulator of activity or of latency or predisposition to hypertension, diabetes, obesity and/or stroke comprising measuring such latency in a test animal, which is prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke, and which recombinantly-expresses a putative modulator of α-tubulin activity, wherein a change in the latency of hypertension, diabetes, obesity and/or stroke within said test animal relative to an analogous animal which is also prone or predisposed to the development of hypertension, diabetes, obesity and/or stroke but does not recombinantly-express the putative modulator, is indicative of the putative modulator possessing the ability to modulate α-tubulin activity or latency or predisposition to hypertension, diabetes, obesity and/or stroke.
 96. The method of claim 95 in which said α-tubulin mutant is screened for an increase in the latency or a decrease in predisposition to hypertension, diabetes, obesity and/or stroke.
 97. A recombinant, non-human animal possessing a mutant SGLT2 gene which is under the control of a promoter which is not the native SGLT2 gene promoter, wherein said mutant SGLT2 gene encodes a mutant SGLT2 which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 98. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant SGLT2 gene sequence.
 99. A recombinant, non-human animal possessing a mutant kynurenine aminotransferase gene which is under the control of a promoter which is not the native kynurenine aminotransferase gene promoter, wherein said mutant kynurenine aminotransferase gene encodes a mutant kynurenine aminotransferase which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 100. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant kynurenine aminotransferase gene sequence.
 101. A recombinant, non-human animal possessing a mutant FAT/CD36 gene which is under the control of a promoter which is not the native FAT/CD36 gene promoter, wherein said mutant FAT/CD36 gene encodes a mutant FAT/CD36 which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 102. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant FAT/CD36 gene sequence.
 103. A recombinant, non-human animal possessing a mutant aldolase A gene which is under the control of a promoter which is not the native aldolase A gene promoter, wherein said mutant aldolase A gene encodes a mutant aldolase A which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 104. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant aldolase A gene sequence.
 105. A recombinant, non-human animal possessing a mutant prepronatriodilatin gene which is under the control of a promoter which is not the native prepronatriodilatin A gene promoter, wherein said mutant prepronatriodilatin A gene encodes a mutant prepronatriodilatin which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 106. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant prepronatriodilatin gene sequence.
 107. A recombinant, non-human animal possessing a mutant α-cardiac myosin gene which is under the control of a promoter which is not the native α-cardiac myosin gene promoter, wherein said mutant α-cardiac myosin gene encodes a mutant α-cardiac myosin which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 108. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant α-cardiac myosin gene sequence.
 109. A recombinant, non-human animal possessing a mutant α-tubulin gene which is under the control of a promoter which is not the native α-tubulin gene promoter, wherein said mutant α-tubulin gene encodes a mutant α-tubulin which either increases the latency or decreases the predisposition to hypertension, diabetes, obesity and/or stroke.
 110. A recombinant, non-human animal which is the product of a process comprising introducing a nucleic acid into said non-human animal, or an ancestor thereof, wherein said nucleic acid comprises a mutant α-tubulin gene sequence. 